



De novo mutations in HCN1 cause early infantile epileptic encephalopathy

Caroline Nava, Carine Dalle, Agnès Rastetter, Pasquale Striano, Carolien de Kovel, Rima Nabbout, Claude Cancès, Dorothée Ville, Eva Brilstra, Giuseppe Gobbi, et al.

► To cite this version:

Caroline Nava, Carine Dalle, Agnès Rastetter, Pasquale Striano, Carolien de Kovel, et al.. De novo mutations in HCN1 cause early infantile epileptic encephalopathy. *Nature Genetics*, 2014, 46 (6), pp.640-645. 10.1038/ng.2952 . hal-01710614

HAL Id: hal-01710614

<https://hal.univ-lorraine.fr/hal-01710614>

Submitted on 3 Jan 2019

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

De novo mutations in HCN1 cause early infantile epileptic encephalopathy

Caroline Nava,^{1-4,24}, Carine Dalle^{5,24}, Agnès Rastetter¹, Pasquale Striano^{6,23}, Carolien G.F. de Kovel⁷, Rima Nabbout^{8,9}, Claude Cancès¹⁰, Dorothée Ville¹¹, Eva H. Brilstra⁷, Giuseppe Gobbi¹², Emmanuel Raffo¹³, Delphine Bouteiller¹⁴, Yannick Marie¹⁴, Oriane Trouillard^{1,3,4}, Angela Robbiano¹⁵, Boris Keren¹⁶, Dahbia Agher¹, Emmanuel Roze¹⁻³, Suzanne Lesage¹⁻³, Aude Nicolas¹⁻³, Alexis Brice¹⁻⁴, Michel Baulac¹⁻³, Cornelia Vogt¹⁷, Nady El Hajj¹⁷, Eberhard Schneider¹⁷, Arvid Suls^{18,19,23}, Sarah Weckhuysen^{18,19,23}, Padhraig Gormley^{20,23}, Anna-Elina Lehesjoki^{21,23}, Peter De Jonghe^{18,19,23}, Ingo Helbig^{22,23}, Stéphanie Baulac^{1-3,23}, Federico Zara^{15,23}, Bobby P.C. Koeleman^{7,23}, EuroEPINOMICS RES consortium, Thomas Haaf¹⁷, Eric LeGuern^{1-4,23}, and Christel Depienne^{1,3,17,23}

¹ Institut National de la Santé et de la Recherche Médicale (INSERM) UMR 975, Institut du cerveau et de la moelle épinière (ICM), Hôpital Pitié-Salpêtrière, Paris, France. ² CNRS 7225, Hôpital Pitié-Salpêtrière, Paris, France. ³ Université Pierre et Marie Curie-Paris-6 (UPMC), UMR_S 975, Paris, France. ⁴ AP-HP, Hôpital Pitié-Salpêtrière, Département de Génétique et de Cytogénétique, Unité Fonctionnelle de Neurogénétique moléculaire et cellulaire, Paris, France. ⁵ ICM, Institut du cerveau et de la moelle épinière, Plateforme d'électrophysiologie, Paris, France. ⁶ Pediatric Neurology and Muscular Diseases Unit, Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genova and Gaslini Institute, Genova, Italy. ⁷ Department of Medical Genetics, University Medical Center Utrecht, Utrecht, The Netherlands. ⁸ Department of Pediatric Neurology, Centre de Reference Epilepsies Rares, Hôpital Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France. ⁹ Institut National de la Santé et de la Recherche Médicale (INSERM) U663, Université Paris Descartes, Sorbonne Paris Cité, Hôpital Necker-Enfants Malades, Paris, France. ¹⁰ Service de neurologie pédiatrique, Hôpital des enfants, Centre Hospitalier Universitaire de Toulouse, Toulouse, France. ¹¹ Service de neurologie pédiatrique, Hôpital Femme Mère Enfant, CHU de Lyon, Bron, France. ¹² Child Neurology Unit, IRCCS Institute of Neurological Sciences of Bologna, Bologna, Italy. ¹³ Service de neuropédiatrie, Hôpital d'enfant de Brabois, CHU de Nancy, Vandoeuvre Les Nancy, France. ¹⁴ ICM, Institut du cerveau et de la moelle épinière, plate-forme de génotypage et séquençage, Paris, France. ¹⁵ Laboratory of Neurogenetics, Department of Neurosciences, Gaslini Institute, Genova, Italy. ¹⁶ AP-HP, Hôpital Pitié-Salpêtrière, Département de Génétique et de Cytogénétique, Unité fonctionnelle de cytogenétique, Paris, France. ¹⁷ Institut für Humangenetik, Universität Würzburg, Würzburg, Germany. ¹⁸ Neurogenetics Group, Department of Molecular Genetics, VIB, Antwerp, Belgium. ¹⁹ Laboratory of Neurogenetics, Institute Born-Bunge, University of Antwerp, Antwerp, Belgium. ²⁰ Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridgeshire, United Kingdom. ²¹ Folkhälsan Institute of Genetics; Research Programs Unit, Molecular Neurology and Neuroscience Center, University of Helsinki, Helsinki, Finland. ²² Department of Neuropediatrics, University Medical Center Schleswig-Holstein, Christian-Albrechts University, Kiel, Germany. ²³ EuroEPINOMICS RES consortium.

²⁴ These authors contributed equally to the study

Correspondence should be addressed to C.De. (christel.depienne@upmc.fr) or E.L.G. (eric.leguern@psl.aphp.fr).

Summary

Hyperpolarization-activated cyclic nucleotide-gated (HCN) channels contribute to cationic Ih current in neurons and regulate the excitability of neuronal networks. Studies in rodent models have shown that the *Hcn1* gene plays a key role in epilepsy, but clinical evidence implicating *HCN1* mutations in human epilepsy is lacking. We carried out exome sequencing for parent-offspring trios with fever-sensitive intractable epileptic encephalopathy, leading to the discovery of two *de novo* missense *HCN1* mutations. The screening of follow-up cohorts comprising 157 patients in total identified four additional amino-acid substitutions. Patch-clamp recordings of Ih currents in cells expressing WT or mutant human HCN1 channels revealed that the mutations had striking, but divergent effects on homomeric channels. Patients with mutations had clinical features resembling those of Dravet syndrome, with progression toward atypical absences, intellectual disability and autistic traits. These findings provide clear evidence that *de novo* *HCN1* point mutations cause a recognizable early-onset epileptic encephalopathy in humans.

Early infantile epileptic encephalopathies (EIEEs) are mostly sporadic disorders characterized by recurrent seizures during the neonatal or infantile periods, with impaired cognitive and motor development. At least 15 different genetically determined forms of EIEE have been recognized^{1,2}. EIEEs typically result from *de novo* dominant mutations in a single autosomal gene, although autosomal recessive and X-linked forms also exist. Dravet syndrome, anintractable epilepsy generally occurring during the first year of life, is the prototype condition: seizures are initially febrile and prolonged, and polymorphic afebrile seizures appear later in the course of the disease. Cognitive and motor development progressively slows, progressing toward intellectual disability (ID)³. Dravet syndrome is mostly caused by *de novo* mutations of *SCN1A*, encoding the neuronal voltage-gated sodium α 1 ($\text{Na}_v1.1$) channel^{4,5}. This syndrome overlaps clinically with *PCDH19*-related epilepsy, an X-linked disorder also associating febrile and afebrile seizures and variable degrees of ID, but expressed only in heterozygous females^{6,7}.

In this study, we carried out whole-exome sequencing on 39 parent-offspring trios including probands with EIEE resembling Dravet syndrome, without *SCN1A* and *PCDH19* mutations. Informed consent was obtained from the families and genetic studies were approved by local ethics committees. The analysis of exome data revealed heterozygous *de novo* mutations (c.299C>T, p.Ser100Phe and c.1201G>C, p.Asp401His) of *HCN1* (NM_021072.2) in two female probands, one French and the other Italian. We then screened 95 additional patients with fever-sensitive EIEE (French cohort) for mutations in *HCN1* coding regions, by amplicon-based pyrosequencing. Three female patients were each found to have a previously unknown nonsynonymous variant (c.140G>T, p.Gly47Val; c.814T>C, p.Ser272Pro; c.890G>C, p.Arg297Thr) in the heterozygous state. The sequencing of available parental DNA showed that p.Ser272Pro and p.Arg297Thr also occurred *de novo*. In parallel, the sequencing of several genes, including *HCN1*, in a Dutch follow-up cohort comprising 62 patients identified the *de novo* c.835C>T (p.His279Tyr) substitution in a male patient. In total, six different heterozygous missense mutations, all confirmed by Sanger sequencing and absent from databases (HapMap, 1000 Genomes, dbSNP137, Exome variant server) were identified in *HCN1* (Fig. 1a). *De novo* occurrence was confirmed for the five mutations for which inheritance could be investigated. The pathogenicity of Gly47Val remained uncertain due to the unavailability of parental DNA.

All patients had similar clinical features including seizures beginning at ages of 4 to 13 months and the combination of febrile and afebrile polymorphic seizures, including hemiclonic and generalized seizures. These features were initially suggestive of Dravet syndrome, but with

a different progression over time. Atypical absences, with or without myoclonic jerks, and focal seizures became predominant in the oldest patients. All patients had mild to severe ID and major behavioral disturbances, including autistic traits (Table 1, Supplementary Table 1).

HCN1 tolerates little functional variation, as only a few missense variants are present in control populations (Supplementary Fig. 1, Supplementary Table 2). Copy number variants (CNV) encompassing *HCN1* exons have been reported in healthy and intellectually disabled individuals, at similar low frequencies (Supplementary Table 3)⁸⁻¹⁰. We recently identified a deletion spanning exon 4 of *HCN1* in a female with sporadic ID and autism spectrum disorder (ASD) but no epilepsy¹¹. Further analyses showed that this deletion was inherited from her asymptomatic father (Supplementary Fig. 2). No second pathogenic mutation was found in the proband, so an autosomal recessive disorder was unlikely. Intragenic *HCN1* deletions alone therefore seem to be insufficient to cause ID and ASD, although they possibly contribute to these disabilities. *HCN1* dysfunction may therefore result in a spectrum of phenotypes, ranging from haploinsufficiency as an inherited risk factor for neurodevelopmental disorders to *de novo* mutations causing EIEE.

HCN1 is one of four genes encoding hyperpolarization-activated cyclic nucleotide-gated channels (HCN) with different biophysical properties, expressed in the heart and brain¹²⁻¹⁴. In neurons, *HCN1* is mainly localized in dendrites¹⁵. HCN subunits have six transmembrane domains and functional channels consist of four subunits. HCN channels are permeable to Na⁺ and K⁺ ions and are activated by membrane hyperpolarization. In the brain, they conduct the Ih current, which contributes to spontaneous rhythmic activity and the stabilization of neuronal membrane potential against excitatory or inhibitory inputs¹⁶. The mutations identified here affect strongly conserved amino acids, except for glycine 47 and, to a lesser extent, serine 100, which are located in less well conserved domains of *HCN1* (Supplementary Fig. 3). The amino acids affected are located in different parts of the channel, but all are intracellular, and four are located close to domains forming the channel pore (Fig. 1b), in particular in the S4-S5 linker, involved in voltage-dependent gating¹⁴.

We assessed the functional consequences of *de novo* mutations identified in EIEE patients, by carrying out patch-clamp recordings on CHO-K1 cells expressing WT or mutant human *HCN1* channels. Voltage-dependent, slowly activating inward currents were recorded in cells expressing the WT, S100F, H279Y and D401H *HCN1* proteins, consistent with the expression of functional channels (Fig. 2a and 2b). These three mutations had major effects on channel gating (Fig. 2c). The half-activation voltage (V_{1/2}) for the S100F and H279Y channels was depolarized by ~27 mV and ~17 mV, respectively, with respect to the WT *HCN1*. D401H *HCN1* was activated at higher positive voltages, due to a 46 mV shift of the activation curve. The S100F and D401H mutations also resulted in significantly faster activation than for WT *HCN1* (Fig. 2d). Furthermore, all three mutations displayed a slower deactivation compared to the WT channel (Fig. 2e). Finally, the S100F mutation also significantly shifted the reversal potential to negative voltage (Supplementary Fig. 4). Altogether, these results indicate that S100F, H279Y and D401H lead to a gain of function (GoF) of homotetrameric *HCN1* channels. By contrast, no Ih current was recorded for cells expressing the S272P and R297T channels (Fig. 2a, Supplementary Fig. 5). These mutant channels were present in lower amounts in cell lysates and at the plasma membrane compared to the WT channels, but similar reduced protein expression, probably due to the instability of the mutated proteins, was also observed for other mutants retaining substantial channel activity, such as S100F (Supplementary Fig. 6), indicating that the loss of function (LoF) were specific to these amino acid changes.

To gain further insights into the mechanisms by which mutations with apparent divergent impacts cause similar phenotypes and to mimic the heterozygous state of the mutations in the patients, we performed co-expression of WT and mutant *HCN1* proteins. Strikingly, R297T *HCN1* and, to a lesser extent, S100F and S272P *HCN1* but not D401H showed a dominant

negative effect on the WT form, by decreasing the current density of heteromeric channels (Fig. 3). These results support the hypothesis that the *de novo* HCN1 mutations identified in this study mostly lead to GoF or dominant negative effects rather than LoF.

I_h current regulates neuronal excitability and the dendritic integration of synaptic potentials in individual neurons and neuronal networks^{13,14,17,18}. HCN1 and HCN2 are the main HCN isoforms expressed in the brain and contributing to this current. HCN1 is predominantly expressed in the neocortex and hippocampus, whereas HCN2 is expressed more evenly, but slightly more strongly in the thalamus than elsewhere^{19,20}. Acquired I_h current dysfunction, due to abnormal *Hcn1* expression or distribution in particular, has been shown to play a crucial role in epileptogenic processes in rodents^{14,16,21,22}. *HCN1* defects were then predicted to contribute to epilepsy in humans as well, and *HCN1* was screened for mutations in patients with idiopathic generalized epilepsy (IGE)^{23,24}. Our results finally provide the first evidence implicating *HCN1* mutations in human epilepsy and show that the associated phenotype is more severe than in the patients with IGE that were previously screened.

Functional studies confirmed that the *de novo* mutations had major impacts on HCN1 function and mostly lead to GoF. However, the precise mechanisms by which mutations cause EIEE in humans remain to be clarified. The observations for LoF mutations were consistent with previous findings describing a decrease in *HCN1* expression occurring very early in epileptogenesis in seizure-induced or spontaneous epileptic rat models²⁵⁻²⁹, and an upregulation of HCN channel function by some antiepileptic drugs^{30,31}. However, rare heterozygous deletions encompassing *HCN1* exons exist in non-epileptic individuals, and *Hcn1*^{-/-} mice have motor learning and memory deficits³² and a higher susceptibility to induced seizures^{33,34}, but display no spontaneous seizures³². These observations suggest that *HCN1* haploinsufficiency, in contrast to point mutations altering channel function, can be functionally tolerated by the developing brain and that HCN1 deficiency promotes neuronal excitability but is insufficient *per se* for seizure development. Proteins with amino acid substitutions are predicted to be present in the cells of patients, with the HCN subunits assembling into functional homo- or heterotetramers¹³. Thus, missense mutations may have dominant negative effects, interfering with the function of the remaining *HCN1* allele, as demonstrated for R297T and S272P, but also with that of *HCN2* in neurons in which they are co-expressed. Consistent with this hypothesis, *Hcn2*^{-/-} mice display spontaneous absence seizures^{35,36}, and a recessive loss-of-function mutation in *HCN2* was recently identified in one patient with IGE³⁷. Alternatively, both increases and decreases in I_h current may be pathological, since both the downregulation and upregulation of *HCN1* expression have been reported, depending on the epileptic rat model^{13,22}. Finally, *HCN1* mutations may have opposite (*i.e.* LoF or GoF) effects depending on the physiological context and cells in which they are expressed, as observed for Na_v1.1 and Nav1.7^{38,39}.

In conclusion, this study provides further evidence of the crucial role of HCN1 and I_h current in human epilepsies. The phenotype of patients with *HCN1*-related encephalopathy, with initial fever-sensitive seizures progressing toward predominant absences and focal seizures, is consistent with HCN1 function and expression, and previous observations of HCN1 channelopathy in animal models of focal or absence epilepsies.

URLs.

HapMap, <http://hapmap.ncbi.nlm.nih.gov/>; 1000 Genomes, <http://www.1000genomes.org/>; dbSNP, <http://www.ncbi.nlm.nih.gov/SNP/>; Exome Variant Server, NHLBI GO Exome Sequencing Project (ESP), Seattle, WA (<http://evs.gs.washington.edu/EVS/>), <http://evs.gs.washington.edu/EVS/>; SIFT, <http://sift.jcvi.org/>; PolyPhen-2, <http://genetics.bwh.harvard.edu/pph2/>.

ACKNOWLEDGMENTS

We thank the patients and their family for their participation in this study, Dr. Juliane Stieber for providing a plasmid containing the human HCN1 cDNA, the International Parkinson's Disease Genomics Consortium (IPDGC) for giving access to the list of *HCN1* variants present in control and PD populations, Lies Van de Velde Boermans for genetic tests for *SCN1A* and *PCDH19* and tests on the parents, Mandy Nizard for patient selection, and Dr Guillaume Huguet and Prof. Thomas Bourgeron for helpful discussions. The research generating these results was funded by the University of Würzburg, Biocodex, *Fondation de France*, ERA-NET NEURON EUHFAUTISM, the “Investissements d’avenir” program ANR-10-IAIHU-06 (IHU-A-ICM), INSERM, AP-HP, the Eurocores program EuroEPINOMICS of the European Science Foundation, the Fund for Scientific Research Flanders (FWO) and University of Antwerp. P.S. and F.Z. thank the Genetics Commission of the Italian League Against Epilepsy (LICE) for their support. B.P.C.K. and C.d.K. were supported by The Netherlands National Epilepsy Fund. A.S. is a postdoctoral fellow of the FWO. C.N., A.B. and C.De. are members of the Bio-Psy Labex.

AUTHOR CONTRIBUTIONS

Clinical and genetic data. *French cohort:* C.De. and C.N. analyzed whole-exome sequencing data. C.N., A.Ra., D.A., D.B., Y.M., C.V., N.E.H., and E.S. contributed to pyrosequencing and/or Sanger sequencing and sequence analysis. B.K. and C.N. contributed to CNV analysis. O.T. performed qPCR. C.C., D.V., R.N. and E.Ra. phenotyped and sampled the patients and provided clinical information. E.Ro. was involved in patient selection. A.B., A.N. and S.L. contributed to variant analysis in populations from the IPDGC. S.B., M.B. and A.B. contributed to study design and discussions. C.De. and E.L.G. supervised the projects related to EIEE, including cohort collection. C.De, E.L.G. and T.H. designed this study. *Dutch cohort:* B.P.C.K and C.G.F.K. designed the study and analyzed sequencing data. B.P.C.K. supervised the study. E.H.B. phenotyped and sampled the patients. *Italian patient:* This patient was included in the EuroEPINOMICS RES consortium. A.S., I.H. and P.G. analyzed whole-exome sequencing data. P.S., A.Ro. and F.Z. contributed to validation of exome sequencing data and supervision of the study. G.G. phenotyped the patient and provided clinical information. P.D.J., I.H., A.S., S.W., and A-E.L. designed the study and/or coordinated projects in the EuroEPINOMICS RES Consortium. **Functional studies** C.N. and A.Ra. performed the site-directed mutagenesis, cell transfections, immunohistochemistry and plasma membrane enrichment experiments. C.Da. performed the electrophysiology analysis and wrote the sections relating to electrophysiology. C.De supervised the collaborative study and drafted the manuscript. All authors critically revised the manuscript.

COMPETING FINANCIAL INTERESTS

The authors have no competing financial interests to declare.

REFERENCES

1. Depienne, C., Gourfinkel-An, I., Baulac, S. & LeGuern, E. Genes in infantile epileptic encephalopathies. (2012).
2. O'Brien, J.E. & Meisler, M.H. Sodium channel SCN8A (Nav1.6): properties and de novo mutations in epileptic encephalopathy and intellectual disability. *Front Genet* 4, 213 (2013).
3. Dravet, C. The core Dravet syndrome phenotype. *Epilepsia* 52 Suppl 2, 3-9 (2011).
4. Claes, L. et al. De novo mutations in the sodium-channel gene SCN1A cause severe myoclonic epilepsy of infancy. *Am J Hum Genet* 68, 1327-32 (2001).

5. Depienne, C. et al. Spectrum of SCN1A gene mutations associated with Dravet syndrome: analysis of 333 patients. *J Med Genet* 46, 183-91 (2009).
6. Depienne, C. et al. Sporadic infantile epileptic encephalopathy caused by mutations in PCDH19 resembles Dravet syndrome but mainly affects females. *PLoS Genet* 5, e1000381 (2009).
7. Dibbens, L.M. et al. X-linked protocadherin 19 mutations cause female-limited epilepsy and cognitive impairment. *Nat Genet* 40, 776-81 (2008).
8. Pinto, D. et al. Comprehensive assessment of array-based platforms and calling algorithms for detection of copy number variants. *Nat Biotechnol* 29, 512-20 (2011).
9. Itsara, A. et al. Population analysis of large copy number variants and hotspots of human genetic disease. *Am J Hum Genet* 84, 148-61 (2009).
10. Cooper, G.M. et al. A copy number variation morbidity map of developmental delay. *Nat Genet* 43, 838-46 (2011).
11. Nava, C. et al. Prospective diagnostic analysis of copy number variants using SNP microarrays in individuals with autism spectrum disorders. *Eur J Hum Genet* 22, 71-8 (2014).
12. Santoro, B. et al. Identification of a gene encoding a hyperpolarization-activated pacemaker channel of brain. *Cell* 93, 717-29 (1998).
13. Benarroch, E.E. HCN channels: function and clinical implications. *Neurology* 80, 304-10 (2013).
14. Biel, M., Wahl-Schott, C., Michalakis, S. & Zong, X. Hyperpolarization-activated cation channels: from genes to function. *Physiol Rev* 89, 847-85 (2009).
15. Lorincz, A., Notomi, T., Tamas, G., Shigemoto, R. & Nusser, Z. Polarized and compartment-dependent distribution of HCN1 in pyramidal cell dendrites. *Nat Neurosci* 5, 1185-93 (2002).
16. Poolos, N.P. Hyperpolarization-Activated Cyclic Nucleotide-Gated (HCN) Ion Channelopathy in Epilepsy. (2012).
17. Kase, D. & Imoto, K. The Role of HCN Channels on Membrane Excitability in the Nervous System. *J Signal Transduct* 2012, 619747 (2012).
18. Nolan, M.F. et al. A behavioral role for dendritic integration: HCN1 channels constrain spatial memory and plasticity at inputs to distal dendrites of CA1 pyramidal neurons. *Cell* 119, 719-32 (2004).
19. Santoro, B. et al. Molecular and functional heterogeneity of hyperpolarization-activated pacemaker channels in the mouse CNS. *J Neurosci* 20, 5264-75 (2000).
20. Bender, R.A. et al. Differential and age-dependent expression of hyperpolarization-activated, cyclic nucleotide-gated cation channel isoforms 1-4 suggests evolving roles in the developing rat hippocampus. *Neuroscience* 106, 689-98 (2001).
21. Chen, K. et al. Persistently modified h-channels after complex febrile seizures convert the seizure-induced enhancement of inhibition to hyperexcitability. *Nat Med* 7, 331-7 (2001).
22. Noam, Y., Bernard, C. & Baram, T.Z. Towards an integrated view of HCN channel role in epilepsy. *Curr Opin Neurobiol* 21, 873-9 (2011).
23. Dibbens, L.M. et al. Augmented currents of an HCN2 variant in patients with febrile seizure syndromes. *Ann Neurol* 67, 542-6 (2010).
24. Tang, B., Sander, T., Craven, K.B., Hempelmann, A. & Escayg, A. Mutation analysis of the hyperpolarization-activated cyclic nucleotide-gated channels HCN1 and HCN2 in idiopathic generalized epilepsy. *Neurobiol Dis* 29, 59-70 (2008).
25. Brewster, A. et al. Developmental febrile seizures modulate hippocampal gene expression of hyperpolarization-activated channels in an isoform- and cell-specific manner. *J Neurosci* 22, 4591-9 (2002).

26. Brauer, A.U. et al. Molecular and functional analysis of hyperpolarization-activated pacemaker channels in the hippocampus after entorhinal cortex lesion. *FASEB J* 15, 2689-701 (2001).
27. Jung, S. et al. Progressive dendritic HCN channelopathy during epileptogenesis in the rat pilocarpine model of epilepsy. *J Neurosci* 27, 13012-21 (2007).
28. Powell, K.L. et al. Decreases in HCN mRNA expression in the hippocampus after kindling and status epilepticus in adult rats. *Epilepsia* 49, 1686-95 (2008).
29. Kole, M.H., Brauer, A.U. & Stuart, G.J. Inherited cortical HCN1 channel loss amplifies dendritic calcium electrogenesis and burst firing in a rat absence epilepsy model. *J Physiol* 578, 507-25 (2007).
30. Surges, R., Freiman, T.M. & Feuerstein, T.J. Gabapentin increases the hyperpolarization-activated cation current Ih in rat CA1 pyramidal cells. *Epilepsia* 44, 150-6 (2003).
31. Munsch, T. & Pape, H.C. Upregulation of the hyperpolarization-activated cation current in rat thalamic relay neurones by acetazolamide. *J Physiol* 519 Pt 2, 505-14 (1999).
32. Nolan, M.F. et al. The hyperpolarization-activated HCN1 channel is important for motor learning and neuronal integration by cerebellar Purkinje cells. *Cell* 115, 551-64 (2003).
33. Santoro, B. et al. Increased seizure severity and seizure-related death in mice lacking HCN1 channels. *Epilepsia* 51, 1624-7 (2010).
34. Huang, Z., Walker, M.C. & Shah, M.M. Loss of dendritic HCN1 subunits enhances cortical excitability and epileptogenesis. *J Neurosci* 29, 10979-88 (2009).
35. Ludwig, A. et al. Absence epilepsy and sinus dysrhythmia in mice lacking the pacemaker channel HCN2. *EMBO J* 22, 216-24 (2003).
36. Chung, W.K. et al. Absence epilepsy in apathetic, a spontaneous mutant mouse lacking the h channel subunit, HCN2. *Neurobiol Dis* 33, 499-508 (2009).
37. DiFrancesco, J.C. et al. Recessive loss-of-function mutation in the pacemaker HCN2 channel causing increased neuronal excitability in a patient with idiopathic generalized epilepsy. *J Neurosci* 31, 17327-37 (2011).
38. Cestele, S., Schiavon, E., Rusconi, R., Franceschetti, S. & Mantegazza, M. Nonfunctional NaV1.1 familial hemiplegic migraine mutant transformed into gain of function by partial rescue of folding defects. *Proc Natl Acad Sci U S A* 110, 17546-51 (2013).
39. Rush, A.M. et al. A single sodium channel mutation produces hyper- or hypoexcitability in different types of neurons. *Proc Natl Acad Sci U S A* 103, 8245-50 (2006).

Additional collaborators of the EuroEPINOMICS RES CONSORTIUM

Rudi Balling²⁵, Nina Barisic²⁶, Hande S. Caglayan²⁷, Dana C. Craiu²⁸, Petia Dimova²⁹, Renzo Guerrini³⁰, Helle Hjalgrim³¹, Dorota Hoffman-Zacharska³², Johanna Jähn²², Karl Martin Klein³³, Vladimir Komarek³⁴, Roland Krause²⁵, Johannes R. Lemke³⁵, Holger Lerche³⁶, Carla Marini³⁰, Patrick May²⁵, Rikke S. Møller³¹, Hiltrud Muhle²², Aarno Paalotie³⁷, Deb Pal³⁸, Felix Rosenow³³, Kaja Selmer³⁹, José M. Serratosa Fernandez⁴⁰, Sanjay Sisodiya⁴¹, Ulrich Stephani²², Katalin Sterbova³⁴, Tiina Talvik⁴², Sarah von Spiczak²², Yvonne Weber³⁶.

²⁵ Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, Esch-sur-Alzette, Luxembourg. ²⁶ Department of Paediatrics, University of Zagreb, Medical School, University Hospital Centre Zagreb, Zagreb, Croatia. ²⁷ Department of Molecular Biology and Genetics, Bogazici University, Istanbul, Turkey. ²⁸ Pediatric Neurology Clinic II, Department of Neurology, Pediatric Neurology, Psychiatry, Neurosurgery, “Carol Davila” University of Medicine, and Pediatric Neurology Clinic, “Professor Doctor Alexandru Obregia” Clinical Hospital, Sector 4, Bucharest, Romania. ²⁹ Clinic of Child Neurology, St Naum University Hospital of Neurology and Psychiatry, Sofia, Bulgaria. ³⁰ Pediatric Neurology Unit and Laboratories, Children's Hospital A. Meyer – University of Florence, Florence, Italy. ³¹ Danish Epilepsy Centre, Dianalund, Denmark. ³² Department of Medical Genetics, Institute of Mother and Child, Warsaw, Poland. ³³ Epilepsy Center Hessen, Department of Neurology, University Hospitals Marburg and Philipps-University Marburg, Marburg, Germany. ³⁴ Child Neurology Department, University Hospital Motol, Praha, Czech Republic. ³⁵ Division of Human Genetics, University Children’s Hospital Inselspital, Bern, Switzerland. ³⁶ Department of Neurology and Epileptology, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany. ³⁷ Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland. ³⁸ Department of Clinical Neuroscience, Institute of Psychiatry, King's College London, London, United Kingdom. ³⁹ Department of Medical Genetics, Oslo University Hospital, Oslo, Norway and Institute of Medical Genetics, University of Oslo, Oslo, Norway. ⁴⁰ Epilepsy Unit, Neurology Service, Hospital Universitario Fundación Jiménez Diaz and Centro De Investigación Biomédica En Red De Enfermedades Raras (CIBERER), Madrid, Spain. ⁴¹ Department of Clinical and Experimental Epilepsy, UCL Institute of Neurology, London, United Kingdom. Epilepsy Society, Buckinghamshire, United Kingdom. ⁴² Department of Pediatrics, University of Tartu, and Department of Neurology and Neurorehabilitation, Children’s Clinic, Tartu University Hospital, Tartu, Estonia.

ONLINE METHODS

Patients

We selected nine trios from the French cohort and 30 from the EuroEPINOMICS RES Consortium for exome sequencing. The inclusion criteria were: normal development before seizure onset, the presence of both febrile and afebrile seizures; the occurrence of polymorphic seizures (tonic-clonic, hemiclonic, myoclonic, absence and/or focal seizures); drug-resistant seizures or *status epilepticus*; developmental delay after seizure onset. All probands had tested negative for *SCN1A* mutations by sequencing and MLPA or Multiplex Amplicon Quantification (MAQ). The follow-up cohorts included 95 additional patients (41 male and 54 female patients) with fever-sensitive epileptic encephalopathy referred for early genetic testing of Dravet syndrome (La Pitié-Salpêtrière, Paris, France) and 62 patients with refractory epileptic encephalopathy and seizure onset within the first four years of age selected from the Dutch cohort (Utrecht, the Netherlands). Informed written consent was obtained from each individual or his/her parents before blood sampling. All experiments were performed in accordance with French guidelines and legislation.

Whole exome sequencing

Exome sequencing for patients N06 0565 and DRA-20 and their unaffected parents was performed by IntegraGen (Evry, France) or the Wellcome Trust Sanger Institute (Hinxton/Cambridge, UK), respectively, as described previously^{40,41}. Exons were captured from fragmented genomic DNA samples using the SureSelect Human All Exon 50Mb (Agilent Technologies) exome kit, and paired-end 75-base massively parallel sequencing was carried out on an Illumina HiSeq2000, according to manufacturers' protocols.

Analysis of whole exome data

Bioinformatics analyses were respectively done using the in-house pipeline developed by Integragen SA, as previously described^{40,41}, or as follows: sequencing reads passing quality filtering were aligned to the human reference genome (hg19) with Burrows-Wheeler Aligner (BWA)⁴². GATK⁴³ was used to recalibrate base quality scores, realign around indels, and mark duplicate reads. Independent variant calling was performed on the mapped reads with SAMtools⁴⁴ mpileup, GATK UnifiedGenotyper and Dindel⁴⁵. For annotating, comparing and filtering the data the GenomeComb⁴⁶ program was used. For the calling of *de novo* variants the DeNovoGear⁴⁷ program by Conrad and colleagues was used and double-checked by GenomeComb analysis.

Screening of *HCN1* by pyrosequencing

Exons and intron-exon junctions of *HCN1* (NM_021072.2) were analyzed by universal tailed amplicon sequencing (454 GS Junior System, Roche), with the exception of the amplicons 3 of exon 8 (8-3), which was screened by Sanger sequencing. Primer pairs (Supplementary Table 4) were designed for exon amplification by PCR; a second PCR was performed to incorporate a multiplex identifier and 454 adaptors, and emulsion PCR was carried out as described in the emPCR Amplification Method Manual (Roche).

Screening of candidate genes including *HCN1* by targeted capture and sequencing

Target enrichment of 340 selected candidate genes, including known epileptic encephalopathy genes and brain-expressed ion channels, was performed using glass slides (Agilent). Barcoded fragment libraries were equimolarly pooled and enriched using multiplexed targeted genomic enrichment. Sequencing was done on a SOliD 5500 (Applied Biosystems). Alignment of reads on the human reference was performed with BWA, and additional bioinformatics steps including filtering for novel coding variants, were done using an in-house pipeline.

Sanger sequencing

Mutations identified by exome sequencing and pyrosequencing were validated by Sanger sequencing with the same primers as for pyrosequencing. Mutations found in patients were directly searched for in available parents by sequencing the corresponding exon. The amplicon 8-3, not covered by pyrosequencing, and exons covered less than 5X by pyrosequencing in some patients were screened by Sanger sequencing. Sequencing reactions were performed on G-50-purified PCR products, with the BigDye Terminator kit. Sequencing products were run on an ABI Prism 3730 DNA Analyzer (Applied Biosystems) and the sequences obtained were analyzed with SeqScape 2.6 software (Applied Biosystems).

Parental testing

Parental testing was carried out with the AmpFl STR SGM plus Kit (Applied Biosystems), to exclude false paternity and DNA inversion, and to check that the mutation had occurred *de novo*.

***In silico* analyses**

The effects of mutations were interpreted with Alamut 2.2 (Interactive Biosoftware). The effects of predicted amino-acid substitutions were assessed with SIFT (<http://sift.jcvi.org/>) and PolyPhen-2 (<http://genetics.bwh.harvard.edu/pph2/>).

Protein sequences of orthologs and paralogs of human HCN1 were retrieved from Uniprot (<http://www.uniprot.org/uniprot/>) and aligned using slow/accurate pairwise alignment defaults parameters with Clustalw (<http://www.genome.jp/tools/clustalw/>).

HCN1 expression plasmids

The plasmid containing the human *HCN1* cDNA was kindly provided by Dr. Juliane Stieber (Institut für Experimentelle und Klinische Pharmakologie und Toxikologie, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany). The S100F, S272P, R297T, H279Y and D401H mutations were introduced into the cDNA with the QuikChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA). All constructs were sequenced to ensure that no additional mutations were introduced.

Cell culture and transfection

CHO-K1 cells (CCL-61, ATCC) were cultured in HAM's F12 medium supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin. Cells were transiently cotransfected with cDNAs encoding the WT or a mutant human HCN1 (hHCN1) channel and pEGFP, with the Neon™ transfection system (Invitrogen), according to the manufacturer's instructions (medium without antibiotic): 1 µg of plasmid cDNA per dish was used for cotransfection, at a ratio of 50:1 (HCN1:pEGFP) for test experiments or with pEGFP alone for control experiments. For coexpression experiments, an equal ratio of WT and mutant (0.5µg of each plasmid) was used in the same conditions. Cells were plated at a density of 5.0×10^5 cells / 40-mm Petri dish for electrophysiological experiments and 2.0×10^6 cells / 100-mm Petri dish for western blot analysis. Cells were incubated for 24 h at 37°C, under an atmosphere containing 5% CO₂, before use.

Patch-clamp technique

Currents were recorded from GFP-expressing cells, with an Axopatch 200B amplifier and a Digidata 1440 analog/digital interface. Pipette resistance was 2-3 MΩ when filled with the intracellular solution containing 120 mM K aspartate, 10 mM NaCl, 10 mM KCl, 1 mM CaCl₂,

10 mM EGTA, 2 mM MgATP and 10 mM HEPES, adjusted to pH 7.2 with KOH. The extracellular solution contained 130 mM NaCl, 15 mM KCl, 0.5 mM MgCl₂, 1.8 mM CaCl₂, 10 mM glucose and 5 mM HEPES adjusted to pH 7.4 with NaOH. Series resistance was typically between 3 and 5 MΩ. Capacitive currents were cancelled and series resistance was compensated by 70 to 80 %. The liquid junction potential was not corrected. Whole-cell currents were low-pass Bessel-filtered at 1 kHz and digitized at 10 kHz. Data were acquired and analyzed with pClamp10 software. Electrophysiological recordings were carried out at room temperature (21-23 °C). Whole-cell voltage-clamp mode was used to investigate the rate and voltage-dependence of channel activation. A series of test pulses, ranging from -140 to +40 mV in 10 mV increments from a holding potential of -20 mV, was applied to the cells for 1 second. Currents were measured in steady state at the end of the test pulses and were normalized with respect to cell capacitance. To obtain voltage-dependent activation curves, tail currents were measured at the fixed voltage of +50 mV immediately after each test pulse, normalized to maximum amplitude tail currents and then plotted against test voltage. Activation curves were fitted with a Boltzmann function:

$$I_t = I_t(\max) / [1 + \exp(V - V_{1/2})/k],$$

where I_t is the current amplitude of the tail current recorded for a given pre-pulse and $I_t(\max)$ is the maximum current amplitude of the tail current, V is voltage of the pre-pulse, $V_{1/2}$ is the half activation voltage and k is the slope factor.

Activation and deactivation time constant were obtained by fitting with a monoexponential function the steady-state current obtained on hyperpolarization at -110mV and the tail current at +10 mV following a conditioning prepulse at -130mV, respectively. Some currents presenting complex kinetic behaviour were not used for analysis. Analysis of raw data, graphical representations and statistical tests were performed with Origin software (OriginLab Corporation), using one-way ANOVA followed by Dunnett's *post hoc* test or two-way ANOVA followed by Bonferroni's post-hoc test for multiple comparison. The significance level was set at $p < 0.05$. All data are reported as means ± SEM.

Additional references

40. Ishida, S. et al. Mutations of DEPDC5 cause autosomal dominant focal epilepsies. *Nat Genet* 45, 552-5 (2013).
41. Suls, A. et al. De Novo Loss-of-Function Mutations in CHD2 Cause a Fever-Sensitive Myoclonic Epileptic Encephalopathy Sharing Features with Dravet Syndrome. *Am J Hum Genet* 93, 967-75 (2013).
42. Li, H. & Durbin, R. Fast and accurate long-read alignment with Burrows-Wheeler transform. *Bioinformatics* 26, 589-95 (2010).
43. McKenna, A. et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. *Genome Res* 20, 1297-303 (2010).
44. Li, H. et al. The Sequence Alignment/Map format and SAMtools. *Bioinformatics* 25, 2078-9 (2009).
45. Albers, C.A. et al. Dindel: accurate indel calls from short-read data. *Genome Res* 21, 961-73 (2011).
46. Reumers, J. et al. Optimized filtering reduces the error rate in detecting genomic variants by short-read sequencing. *Nat Biotechnol* 30, 61-8 (2012).
47. Conrad, D.F. et al. Variation in genome-wide mutation rates within and between human families. *Nat Genet* 43, 712-4 (2011).

Table 1 Genetic and clinical characteristics of the patients with *HCN1* mutations identified in this study

Family number	6	2	3	5	4	1
Patient origin	France	Italy	France	The Netherlands	France	France
Sex	Female	Female	Female	Male	Female	Female
Base change	c.140G>T	c.299C>T	c.814T>C	c.835C>T	c.890G>C	c.1201G>C
Amino acid change	p.Gly47Val	p.Ser100Phe	p.Ser272Pro	p.His279Tyr	p.Arg297Thr	p.Asp401His
Exon	1	1	2	2	3	4
Inheritance	?	<i>De novo</i>	<i>De novo</i>	<i>De novo</i>	<i>De novo</i>	<i>De novo</i>
Current age (years)	13	6	16	12	15	18
Age at seizure onset (months)	7	10	8	13	8	4
Seizure types	FS, TCS, absences, focal, myoclonic seizures	FS, TCS, CS, absences, focal, myoclonic seizures	FS, CS, focal seizures, absences	FS (atypical), CS, TCS, absences, myoclonic seizures	FS, focal seizures, absences	FS, TCS, absences, focal, myoclonic seizures
<i>Status epilepticus</i>	yes	no	yes	no	yes	yes
ID	Moderate/severe	Moderate	Severe	Mild	Moderate/severe	Moderate/severe
MRI	NA	Normal	Normal	Normal	Normal	Normal
Pharmacoresistance	yes	yes	yes	yes	yes	yes
Behavior and language	Absence of language	Autistic features	Behavioral disturbances, autistic features	Behavioral disturbances; ADHD	Behavioral disturbances, autistic features	Behavioral disturbances, autistic features
Other features	Ataxia	None	Motor delay	Truncal ataxia	None	Polyphagia

FS: febrile seizures, TCS: tonic-clonic seizures, CS: clonic seizures, ID: intellectual disability, ADHD: attention deficit hyperactivity disorder; NA: unavailable

FIGURE LEGENDS




Figure 1 Identification of *HCN1* missense mutations. **(a)** Pedigrees and segregation analysis of the six *HCN1* missense variants identified in this study. The arrows indicate the probands. p.Ser100Phe, p.Ser272Pro, p.Arg297Thr, p.His279Tyr and p.Asp401His were absent from both parents, indicating that they occurred *de novo* in the probands. Segregation analysis could not be performed for the p.Gly47Val variant, because parental DNA samples were not available. **(b)** Schematic diagram of the HCN1 channel, showing the location of the amino acids affected by the missense mutations identified in this study (stars).




Figure 2 Patch-clamp analysis of the functional impact of the *de novo* HCN1 mutations. **(a)** Representative traces of whole-cell currents recorded from CHO-K1 cells transfected with pEGFP, reflecting the endogenous current (control), WT, S100F, H279Y, R297T, S272P or D401H hHCN1 channels. The arrow indicates the zero current level. **(b)** Plot of mean current density as a function of test voltage for WT, S100F, H279Y and D401H hHCN1 channels. Current densities did not differ significantly between the WT and mutant channels ($p>0.05$), except for the D401H mutant (two-way ANOVA, * $p<0.05$ for voltage -140 mV to -60 mV). **(c)** Mean tail current activation curve for the WT, S100F, H279Y and D401H hHCN1 channels. Red lines show fits of a Boltzmann function providing the half-activation voltage $V_{1/2}$ and slope factor (k) for the WT: -72.06 ± 0.73 mV, $k = 13.1 \pm 0.5$ mV, S100F: -44.59 ± 1.91 mV, $k = 23.9 \pm 1.3$ mV; H279Y: -54.76 ± 1.49 mV, $k = 22.4 \pm 1.1$ mV; D401H: -25.54 ± 0.96 mV, $k = 24.5 \pm 0.8$ mV. **(d)** The D401H and S100F mutant channels had higher activation time constants than the WT hHCN1 channel (one-way ANOVA, *** $p<0.001$). **(e)** The three mutant channels displayed enhanced deactivation time constants compared with those of the WT hHCN1 (one-way ANOVA, * $p < 0.05$ and *** $p < 0.001$). Data are presented as means \pm SEM, with the numbers of experiments indicated in brackets and SEM indicated by error bars.




Figure 3 Data analysis of co-expression of WT and mutant hHCN1 channels with the patch clamp technique. **(a)** Plot of mean current density as a function of test voltage for CHO-K1 cells transfected with pEGFP, reflecting endogenous current (control), 0.5 µg WT, 1 µg WT, WT+S272P, WT+R297T and WT+D401H hHCN1 channels. Identical amount of WT and mutant cDNA (i.e. 0.5 µg) were cotransfected. Current density of WT+S100F, WT+S272P, and WT+R297T hHCN1 channels were significantly different compared with current density of WT (1 µg) channels (two-way ANONA, *** $p < 0.001$). **(b)** Bar graph of current densities for each experimental group at -140 mV. **(c)** Mean tail current activation curve for 0.5 µg WT, 1 µg WT, WT+S272P, WT+R297T, and WT+D401H hHCN1 channels. Red lines show fits of a Boltzmann function (online methods) providing the half-activation voltage $V_{1/2}$ and slope factor (k) for 1 µg WT: -72.06 ± 0.73 mV, $k = 13.1 \pm 0.5$ mV; 0.5 µg WT: -75.22 ± 0.91 mV, $k = 14.63 \pm 0.7$ mV; WT+S100F: -69.51 ± 0.99 mV, $k = 20.7 \pm 0.8$ mV, WT+S272P: -70.38 ± 1.68 mV, $k = 27.3 \pm 1.4$ mV; WT+D401H: -62.98 ± 1.33 mV, $k = 20.8 \pm 0.9$ mV. **(d)** The WT+D401H hHCN1 channels had higher activation time constants than the WT channels (one-way ANOVA, * $p < 0.05$). Data are presented as means \pm SEM, with the numbers of experiments given in brackets and SEM indicated by error bars.

Supplementary information

De novo mutations in HCN1 cause early infantile epileptic encephalopathy


Caroline Nava^{1–4,24}, Carine Dalle^{1,5,24}, Agnès Rastetter¹, Pasquale Striano⁶, Carolien G F de Kovel⁷, Rima Nabbout^{8,9}, Claude Cancès¹⁰, Dorothée Ville¹¹, Eva H Brilstra⁷, Giuseppe Gobbi¹², Emmanuel Raffo¹³, Delphine Bouteiller¹⁴, Yannick Marie¹⁴, Oriane Trouillard^{1,3,4}, Angela Robbiano¹⁵, Boris Keren⁴, Dahbia Agher¹, Emmanuel Roze^{1–3}, Suzanne Lesage^{1–3}, Aude Nicolas^{1–3}, Alexis Brice^{1–4}, Michel Baulac^{1–3}, Cornelia Vogt¹⁶, Nady El Hajj¹⁶, Eberhard Schneider¹⁶, Arvid Suls^{17,18}, Sarah Weckhuysen^{17,18}, Padhraig Gormley¹⁹, Anna-Elina Lehesjoki^{20,21}, Peter De Jonghe^{17,18}, Ingo Helbig²², Stéphanie Baulac^{1–3}, Federico Zara¹⁵, Bobby P C Koeleman⁷, EuroEPINOMICS RES Consortium²³, Thomas Haaf¹⁶, Eric LeGuern^{1–4} & Christel Depienne^{1,3,16}

¹INSERM UMR 975, Institut du Cerveau et de la Moelle Epinière, Hôpital Pitié-Salpêtrière, Paris, France. ²CNRS 7225, Hôpital Pitié-Salpêtrière, Paris, France. ³Université Pierre et Marie Curie–Paris 6 (UPMC), UMRS 975, Paris, France. ⁴Assistance Publique–Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, Département de Génétique et de Cytogénétique, Unité Fonctionnelle de Neurogénétique Moléculaire et Cellulaire, Paris, France. ⁵Institut du Cerveau et de la Moelle Epinière, Plateforme d'Electrophysiologie, Paris, France. ⁶Pediatric Neurology and Muscular Diseases Unit, Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, 'G Gaslini Institute', Genova, Italy. ⁷Department of Medical Genetics, University Medical Center Utrecht, Utrecht, The Netherlands. ⁸Department of Pediatric Neurology, Centre de Référence Epilepsies Rares, Hôpital Necker–Enfants Malades, AP-HP, Paris, France. ⁹INSERM U663, Université Paris Descartes, Sorbonne Paris Cité, Hôpital Necker–Enfants Malades, Paris, France. ¹⁰Service de Neurologie Pédiatrique, Hôpital des Enfants, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.



¹¹Service de Neurologie Pédiatrique, Hôpital Femme Mère Enfant, Centre Hospitalier Universitaire de Lyon, Bron, France. ¹²Child Neurology Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Institute of Neurological Sciences of Bologna, Bologna, Italy. ¹³Service de Neuropédiatrie, Hôpital d'Enfant de Brabois, Centre Hospitalier Universitaire de Nancy, Vandoeuvre Les Nancy, France.

¹⁴Institut du Cerveau et de la Moelle Epinière, Plateforme de Génotypage et Séquençage, Paris, France. ¹⁵Laboratory of Neurogenetics, Department of Neurosciences, Gaslini Institute, Genova, Italy.

¹⁶Institut für Humangenetik, Universität Würzburg, Würzburg, Germany. ¹⁷Neurogenetics Group, Department of Molecular Genetics, VIB, Antwerp, Belgium. ¹⁸Laboratory of Neurogenetics, Institute Born-Bunge, University of Antwerp, Antwerp, Belgium. ¹⁹Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, UK. ²⁰Folkhälsan Institute of Genetics, Helsinki, Finland. ²¹Research Programs Unit, Molecular Neurology and Neuroscience Center, University of Helsinki, Helsinki, Finland. ²²Department of Neuropediatrics, University Medical Center Schleswig-Holstein, Christian Albrechts University, Kiel, Germany. ²³Full lists of members and affiliations appear at the end of the paper. ²⁴These authors contributed equally to this work.



Supplementary Figure 1 Comparison of the mean number of rare variants per base and per individual between *HCN1* and selected genes expressed in the brain. The numbers of truncating variants (nonsense and splice site), rare missense variants (with MAF < 1%), very rare missense variants (present in fewer than ten individuals) and very rare missense variants predicted to be possibly or probably damaging by Polyphen-2 per base and per individual have been calculated for selected genes expressed in the brain, associated with autosomal dominant epilepsies or epileptic encephalopathies (*SCN1A*, *SCN2A*, *SCN8A*, *SCN1B*, *CHD2*, *STXBP1*, *KCNT1*, *GRIN2A*, *GRIN2B*, *SYNGAP1*), autosomal recessive various phenotypes (*CLCN2*, *EPM2A*, *NHLRC1*, *POLG*, *RELN*) and X-linked epileptic encephalopathy (*PCDH19*) and for genes associated with complex phenotypes (*DRD4*) or no known disorder in humans (*HTR3B*), from data of the European ESP population (Exome Variant Server, <http://evs.gs.washington.edu/EVS/>).



Supplementary Figure 2 Identification of a heterozygous deletion encompassing exon 4 of *HCN1* in a female subject with ID and ASD, inherited from her asymptomatic father. **(a)** Cyto-12 SNP array (Illumina) profiles of the patient with *HCN1* exon 4 deletion and details of the coding sequences included the deletion: the y axis indicates the B allele frequency (above) and the log R ratio (below), and the x axis indicates the position on chromosome 5. The deletion spans ~33 kb and theoretically leads to an in-frame deletion of 73 amino acids (p.Asn338_Lys410del) in the extracellular loop between the S5 and S6 domains containing the pore region. **(b)** Confirmation of the presence of the *HCN1* heterozygous deletion in the proband and her father by quantitative PCR using primers located on exon 4 (forward: 5'-CCACCTGCTATGCCATGTTT-3'; reverse: 5'-ATACTGCCGCCTCGAAGsAAT-3'). RT-PCR experiments were performed using 10 ng of genomic DNA, 0.8 μM of each primer and 12.5 μl of SYBR Green PCR master mix (Applied Biosystems) in a total volume of 25 μl. RNase P (RNase P Control Assay, Applied Biosystems) was used as the reference amplicon. Each sample was run in triplicate on an ABI PRISM 7700 Detection System (Applied Biosystems), and three different experiments were used for final quantification. Relative ratios were calculated using the formula $r = 2^{-\Delta\Delta C_t}$ with $\Delta\Delta C_t = (C_{t \text{ mutation}} - C_{t \text{ RNaseP}})_{\text{ind tested}} - (C_{t \text{ mutation}} - C_{t \text{ RNaseP}})_{\text{ind ref}}$.

47

HCN1_HUMAN	PPGGGGAGA K E H GNSVCFK
HCN1_MACAQUE	PPGGGGAGA K E H GNSVCFK
HCN1_ORANGUTAN	PPGGGGAGA K E H GNSVCFK
HCN1_MARMOSET	PPGGGGAGA K E H GNSVCFK
HCN1_MOUSE	PPGGG-AAG K E H GNSVCFK
HCN1_RAT	PPGGG-AAG K E H GNSVCFK
HCN1_COW	PPGGGGTG K A E HGNSVCFK
HCN1_GALAGO	PPGGGGAGA K E H GNSVCFK
HCN1_DOG	PPGGGGAGA K E H GNSVCFK

HCN1_HUMAN	
HCN1_MACAQUE	
HCN1_ORANGUTAN	
HCN1_MARMOSET	
HCN1_MOUSE	
HCN1_RAT	
HCN1_COW	
HCN1_DOG	
HCN1_PANDA	
HCN1_RABBIT	
HCN1_BIRD	
HCN1_CHICKEN	
HCN1_FROG	
HCN1_TETRAODON	

100

QRQFTS M LQPGVNKF S LRMF G S Q K
QRQFTS M LQPGVNKF S LRMF G S Q K
QRQFTS M LQPGVNKF S LRMF G S Q K
QRQFTS M LQPGVNKF S LRMF G S Q K
QRQFTS M LQPGVNKF S LRMF G S Q K
QRQFTS M LQPGVNKF S LRMF G S Q K
QRQFTS M LQPGVNKF S LRMF G S Q K
QRQFTS M LQPGVNKF S LRMF G S Q K
QRQFTS M LQPGVNKF S LRMF G S Q K
QRQFTS M LQPGVNKF S LRMF G S Q K
QRQFTS M LQPGVNKF S LRMF G S Q K
QRQFTS M LQPGVNKF S LRMF G S Q K
QRQFTS M LQPGVNKF S LRMF G S Q K
QRQFTS M LQPGVNKF S LRMF G S Q K
QRQFTS M LQPGVNKF S LRMF G S Q K

272 279


HCN1_HUMAN	LLRLLRLS R LIRYI H QWE E IFHMTYD L ASAV V R I FNLIGM M
HCN1_MACAQUE	LLRLLRLS R LIRYI H QWE E IFHMTYD L ASAV V R I FNLIGM M
HCN1_ORANGUTAN	LLRLLRLS R LIRYI H QWE E IFHMTYD L ASAV V R I FNLIGM M
HCN1_MARMOSET	LLRLLRLS R LIRYI H QWE E IFHMTYD L ASAV V R I FNLIGM M
HCN1_MOUSE	LLRLLRLS R LIRYI H QWE E IFHMTYD L ASAV V R I FNLIGM M
HCN1_RAT	LLRLLRLS R LIRYI H QWE E IFHMTYD L ASAV V R I FNLIGM M
HCN1_COW	LLRLLRLS R LIRYI H QWE E IFHMTYD L ASAV V R I FNLIGM M
HCN1_DOG	LLRLLRLS R LIRYI H QWE E IFHMTYD L ASAV V R I FNLIGM M
HCN1_PANDA	LLRLLRLS R LIRYI H QWE E IFHMTYD L ASAV V R I FNLIGM M
HCN1_RABBIT	LLRLLRLS R LIRYI H QWE E IFHMTYD L ASAV V R I FNLIGM M
HCN1_BIRD	LLRLLRLS R LIRYI H QWE E IFHMTYD L ASAV V R I FNLIGM M
HCN1_CHICKEN	LLRLLRLS R LIRYI H QWE E IFHMTYD L ASAV V R I FNLIGM M
HCN1_FROG	LLRLLRLS R LIRYI H QWE E IFHMTYD L ASAV V R I FNLIGM M
HCN1_TETRAODON	LLRLLRLS R LIRYI H QWE E IFHMTYD L ASAV V R I FNLIGM M

297


GHATALIQSL D SSRRQ Y QE K Y
GHATALIQSL D SSRRQ Y QE K Y
GHATALIQSL D SSRRQ Y QE K Y
GHATALIQSL D SSRRQ Y QE K Y
GHATALIQSL D SSRRQ Y QE K Y
GHATALIQSL D SSRRQ Y QE K Y
GHATALIQSL D SSRRQ Y QE K Y
GHATALIQSL D SSRRQ Y QE K Y
GHATALIQSL D SSRRQ Y QE K Y
GHATALIQSL D SSRRQ Y QE K Y
GHATALIQSL D SSRRQ Y QE K Y
GHATALIQSL D SSRRQ Y QE K Y
GHATALIQSL D SSRRQ Y QE K Y
GHATALIQSL D SSRRQ Y QE K Y
GHATALIQSL D SSRRQ Y QE K Y

401


Supplementary Figure 3 Alignment of the regions flanking the six missense variants in orthologous proteins, showing the conservation of the altered amino acids. Multiple pairwise alignments were performed using ClustalW 2.1 (<http://www.genome.jp/tools/clustalw/>). The amino acids altered by the mutations are highlighted. Full alignments including all species are provided as a Supplementary Note.



Supplementary Figure 4 Reversal potential (E_{rev}) of gain-of-function mutations affecting the hHCN1 channel. (a) Representative whole-cell current trace recorded from a CHO-K1 cell transfected with construct for wild-type (WT) hHCN1 channel. For determination of E_{rev} , currents were fully activated by a prepulse to -130 mV for 1 s from a holding potential of -20 mV, and test pulses were then applied from -100 mV to $+40$ mV in 10-mV increments, with tail current measured immediately after the prepulse. (b) Plot of mean tail current density as a function of test voltage for WT, S100F, H279Y and D401H hHCN1 channels. The number of cells for each condition is indicated in parentheses. The red line represents a linear regression through the mean values for the tail current density and is used to obtain E_{rev} . (c) Bar graph of E_{rev} for WT hHCN1 and the three mutant channels (one-way ANOVA followed by a Dunnett's test, *** $P < 0.001$). Data are represented as mean values \pm s.e.m. with numbers of experiments given in parentheses.



Supplementary Figure 5 Data analysis of loss-of-function mutations affecting the hHCN1 channel identified with the patch clamp technique. Plot of mean current density as a function of test voltage for control cells (cells transfected only with pEGFP plasmid, reflecting the endogenous current) and cells expressing S272P and R297T mutant channels. The number of cells for each condition is indicated in parentheses. Currents were elicited by test pulses ranging from -140 mV to +40 mV in 10-mV increments from a holding potential of -20 mV and were normalized to cell capacitance (representative traces in Fig. 2a). Current densities of both mutant channels were not significantly different compared with endogenous currents from control cells (one-way ANOVA followed by a Dunnett's test, $P > 0.05$). Data are presented as means \pm s.e.m. with numbers of experiments given in parentheses.



Supplementary Figure 6 Impact of *de novo* HCN1 mutations on protein expression and localization at the plasma membrane. (a) Semiquantitative analysis of WT and mutant (S100F, S272P, R297T, H279Y or D401H) HCN1 protein expression in whole-cell lysates and at the plasma membrane by protein blot. CHO-K1 cells were transiently cotransfected with 12 µg of WT or mutant HCN1 expression plasmid using the Neon electroporation system (Invitrogen); 24 h after transfection, proteins present at the plasma membrane were isolated using the Cell Surface Protein Isolation kit (Pierce), following the manufacturer's recommendations. Whole-cell lysates were kept before isolation of membrane protein from the same experiments. Proteins present in both fractions were resolved by SDS-PAGE on 4–12% gradient gels (Invitrogen) and electrotransferred onto nitrocellulose membranes. HCN1 was probed using a monoclonal mouse anti-HCN1 antibody (ab84816, Abcam; 1:10,000 dilution), and the signal was visualized with enhanced chemiluminescence (Pierce). Membranes were probed with anti-Flotillin-1 antibody (610820, BD Biosciences; 1:1,000 dilution) for normalization. The image shows the result of a representative experiment. (b) Semiquantitative measurement of WT and mutant HCN1 proteins present in whole-cell lysates (blue) and at the plasma membrane (red) from three independent experiments using the ImageJ program (<http://rsb.info.nih.gov/ij/>). The values obtained for WT and mutant HCN1 proteins were corrected for the intensity of the corresponding flotillin bands. Data are presented as means ± s.e.m. Note that, although the expression of S100F, S272P and R297T HCN1 channels was similarly decreased, an I_h current was recorded for S100F but not for S272P and R297T. In addition, the S272P and R297T mutants showed a dominant-negative effect on the WT-mutant heteromeric channels, suggesting that mutant homomeric channels are less stable than WT-mutant heteromeric channels. (c) Effect of proteasome inhibition on mutant (S100F, S272P, R297T, H279Y or D401H) HCN1 protein expression in whole-cell lysates. CHO-K1 cells were transiently cotransfected with WT or mutant HCN1 expression plasmids; 24 h after transfection, half of the cells was treated with 1 µM epoxomicin (E3652, Sigma) for 16 h. Proteins were then resolved by SDS-PAGE on 4–12% gradient gels (Invitrogen) and electrotransferred onto nitrocellulose membranes. HCN1 was probed using the monoclonal mouse anti-HCN1 antibody, and the signal was detected by enhanced direct near-infrared fluorescence detection system (LI-COR Biosciences). Membranes were probed with anti-actin antibody (ab3280, Abcam; 1:4,000 dilution) for normalization. The image shows the result of a representative experiment.

Family number/ Patient ID	6 / N09 2300	2/ DRA-20	3/ N 07 1339	5/ 2008D01179	4/ N10 0713	1/ N06 0565
Patient origin	France	Italy	France	The Netherlands	France	France
Sex	Female	Female	Female	Male	Female	Female
Base change	c.140G>T	c.299C>T	c.814T>C	c.835C>T	c.890G>C	c.1201G>C
Amino acid change	p.Gly47Val	Ser100Phe	p.Ser272Pro	p.His279Tyr	p.Arg297Thr	p.Asp401His
Exon	1	1	2	2	3	4
Inheritance	Unknown	<i>De novo</i>	<i>De novo</i>	<i>De novo</i>	<i>De novo</i>	<i>De novo</i>
<i>In silico</i> predictions (SIFT / Polyphen-2)	Deleterious / Benign	Deleterious / Possibly damaging	Deleterious / Possibly damaging	Deleterious / Possibly damaging	Deleterious / Possibly damaging	Deleterious / Probably damaging
Age at time of analysis (years)	13	6	16	12	15	18
Age at seizure onset (months)	7	10	8	13	8	4
Seizure type at onset	Febrile, TCS	Febrile and afebrile, TCS	Febrile, hemiclonic	Febrile seizures (atypical)	Febrile, hemiclonic (left / right) seizures	TCS, cyanosis
Seizure types during disease course	TCS, atypical absences with or without myoclonic jerks; focal seizures, seizures in clusters	Clonic seizures, TCS, atypical absences, myoclonic jerks, focal (frontal?) seizures	Clonic seizures, atypical absences, focal seizures	Clonic seizures, TCS, tonic, atypical absences, myoclonic jerks, nocturnal seizures	Hemiclonic seizures, atypical absences, nocturnal frontal seizures, focal seizures, drop attacks	TCS, myoclonic jerks, atypical absences, nocturnal frontal seizures
Febrile seizures	yes	yes	yes	yes	yes	yes
Status epilepticus	yes	no	yes	no	yes	yes

Frequency of seizures	Several per month before 3 years, several per year thereafter	Several per week, clusters	Several per month	Several per week at onset; several per year later on; absences and myoclonic jerks: several days per week	Several per week at onset; seizure-free between the ages of 2 and 6 yrs, with STP,VPA CLB; Rare seizures between 6 and 10 yrs of age; several seizures per week from the age of 10 yrs	Several per week at onset; several absences per day and several nocturnal seizures per month later on
ID	Moderate/severe	Moderate	Severe	Mild	Moderate/severe	Moderate/severe
MRI	NA	Normal	Normal	Normal	Normal	Normal
EEG	NA	GSW	Normal then multifocal spikes, slowing	Diffuse (poly)peakwave complexes; later on: multifocal epileptic discharges with frontocentral maximum	8 months: normal 9 months: diffuse PSW, IPS+ ; 9 yrs: frontal synchronous spike and wave with activation during sleep	PSW
Pharmacoresistance	yes	yes	yes	yes	yes	yes
AEDs	VPA, CLB	LTG, CLB, VPA, PB	VPA, CLB, STP	ETX, LTG	VPA, CLB, STP, TPM, ZNS, LVT, LTG, ketogenic diet, VNS	VPA, CLB, TPM
Behavior and language	Absence of language	Autistic features	Behavioral disturbances, autistic features, stereotypies	Behavioral disturbances; agitation, attention deficit disorder	Behavioral disturbances, autistic features	Autistic features, agitation, aggressiveness, stereotypies
Other features	Ataxia	None	Motor delay	Truncal ataxia	None	Polyphagia

Supplementary Table 1 Detailed genetic and clinical characteristics of the patients with *HCN1* mutations identified in this study.

TCS: tonic-clonic seizures, yrs: years, ID: intellectual disability, AED: antiepileptic drug, VPA: sodium valproate, CLB: clobazam, STP: stiripentol, TPM: topiramate, ZNS: zonisamide, LVT: levetiracetam, LTG: lamotrigine, ETX: ethosuximide, VNS: Vagus Nerve stimulation; GSW: generalized spike waves, PSW: polyspike waves, IPS: intermittent photic stimulation, NA: unavailable.

Population	Chrom	Position	Ref base	Sample base	Gene	Transcript	Transcript Variant	Protein Variant	Number of ind (EA/AA)	Impact	SIFT Prediction	PolyPhen-2 Prediction	RsNumber
PD	5	45696129	C	A	HCN1	NM_021072.3	c.67G>T	p.Ala23Ser	1	missense	Tolerated	Benign	
PD	5	45695967	G	T	HCN1	NM_021072.3	c.229C>A	p.Pro77Thr	1	missense	Tolerated	Benign	
ESP	5	45695964	C	T	HCN1	NM_021072.3	c.232G>A	p.Ala78Thr	0/1	missense	Tolerated	Benign	
ESP	5	45695937	G	A	HCN1	NM_021072.3	c.259C>T	p.Pro87Ser	0/1	missense	Deleterious	Benign	
ESP	5	45695900	G	A	HCN1	NM_021072.3	c.296C>T	p.Thr99Ile	1/0	missense	Tolerated	Benign	rs143865339
ESP	5	45645537	T	C	HCN1	NM_021072.3	c.599A>G	p.Asn200Ser	1/0	missense	Tolerated	Benign	
ESP	5	45645433	T	C	HCN1	NM_021072.3	c.703A>G	p.Ile235Val	1/0	missense	Deleterious	Benign	
ESP	5	45462005	T	G	HCN1	NM_021072.3	c.954A>C	p.Leu318Phe	1/0	missense	Deleterious	Possibly damaging	
ESP	5	45461997	A	G	HCN1	NM_021072.3	c.962T>C	p.Leu321Pro	1/0	missense	Deleterious	Benign	rs149434809
											Probably		
ESP	5	45396611	G	A	HCN1	NM_021072.3	c.1213C>T	p.Arg405Trp	1/0	missense	Deleterious	damaging	
ESP	5	45353327	T	G	HCN1	NM_021072.3	c.1252A>C	p.Met418Leu	1/0	missense	Deleterious	Possibly damaging	
											Probably		
ESP	5	45353314	T	G	HCN1	NM_021072.3	c.1265A>C	p.Lys422Thr	1/0	missense	Deleterious	damaging	rs140166527
											Probably		
ESP	5	45353231	G	A	HCN1	NM_021072.3	c.1348C>T	p.Leu450Phe	1/0	missense	Deleterious	damaging	rs146123836
PD	5	45303809	G	A	HCN1	NM_021072.3	c.1510C>T	p.Arg504*	1	stop gain			
CI	5	45303797	C	T	HCN1	NM_021072.3	c.1522G>A	p.Val508Met	1	missense	Deleterious	Benign	
CI, PD	5	45262760	T	A	HCN1	NM_021072.3	c.1936A>T	p.Thr646Ser	1, 1	missense	Tolerated	Benign	
PD	5	45262715	T	A	HCN1	NM_021072.3	c.1981A>T	p.Arg661Trp	1	missense	Deleterious	Possibly damaging	
ESP	5	45262714	C	T	HCN1	NM_021072.3	c.1982G>A	p.Arg661Lys	0/1	missense	Deleterious	Benign	rs143224211
ESP	5	45262688	C	T	HCN1	NM_021072.3	c.2008G>A	p.Ala670Thr	1/0	missense	Deleterious	Benign	
ESP	5	45262687	G	A	HCN1	NM_021072.3	c.2009C>T	p.Ala670Val	2/1	missense	Deleterious	Benign	rs142280884
ESP	5	45262675	G	A	HCN1	NM_021072.3	c.2021C>T	p.Ser674Phe	0/1	missense	Deleterious	Benign	rs138171983
ESP	5	45262619	T	C	HCN1	NM_021072.3	c.2077A>G	p.Ile693Val	1/0	missense	Tolerated	Benign	
ESP	5	45262591	G	A	HCN1	NM_021072.3	c.2105C>T	p.Ala702Val	3/0	missense	Deleterious	Possibly damaging	rs147007826
ESP	5	45262564	G	A	HCN1	NM_021072.3	c.2132C>T	p.Pro711Leu	0/2	missense	Deleterious	Possibly damaging	
ESP	5	45262526	C	T	HCN1	NM_021072.3	c.2170G>A	p.Ala724Thr	0/6	missense	Deleterious	Possibly damaging	rs141383188
ESP	5	45262387	G	A	HCN1	NM_021072.3	c.2309G>A	p.Ser770Asn	0/1	missense	Deleterious	Benign	
ESP	5	45262375	A	G	HCN1	NM_021072.3	c.2321T>C	p.Leu774Pro	0/2	missense	Deleterious	Possibly damaging	rs149702217
											Probably		
ESP	5	45262321	G	A	HCN1	NM_021072.3	c.2375C>T	p.Ser792Leu	0/1	missense	Deleterious	damaging	rs140758934
PD	5	45262306	A	C	HCN1	NM_021072.3	c.2390T>G	p.Val797Gly	1	missense	Tolerated	Benign	
ESP	5	45262234	C	T	HCN1	NM_021072.3	c.2462C>T	p.Ala821Val	1/0	missense	Tolerated	Benign	
PD	5	45262211	C	A	HCN1	NM_021072.3	c.2485G>T	p.Ala829Ser	1/0	missense	Tolerated	Benign	
ESP	5	45262189	C	T	HCN1	NM_021072.3	c.2507C>T	p.Pro836Leu	1/0	missense	Deleterious	Possibly damaging	
ESP	5	45262137	C	G	HCN1	NM_021072.3	c.2559C>G	p.Asn853Lys	1/0	missense	Tolerated	Benign	rs140186173
ESP	5	45262106	C	T	HCN1	NM_021072.3	c.2590G>A	p.Ala864Thr	0/1	missense	Deleterious	Benign	

ESP	5	45262090	C	T	HCN1	NM_021072.3	c.2606G>A	p.Arg869Lys	0/1	missense	Tolerated	Benign
CI	5	45262037	C	T	HCN1	NM_021072.3	c.2659G>A	p.AlaA887Thr	1	missense	Tolerated	Benign

Supplementary Table 2 Summary of *HCN1* variants present in the ESP population and in cases with Parkinson's disease (PD, $n = 1,407$) and control individuals (CI, $n = 530$) included in the IPDGC study.

A total of 27 missense variants, all in the heterozygous state, in 38 individuals (Frequency of heterozygotes $38/6503=0.0058$) are present in the ESP population. This list does not include the frequent polymorphic in-frame deletions in the glycine stretch (c.199-207delGGTGGCGGC, p.67delGGG; c.214-222delGGCGCGGC, p.72delGGG; c.217-222delGGCGGC, p.73delGG) previously described in exon 1 of *HCN1*.^{23,24}

The frequency of *HCN1* heterozygous variants is identical in two other populations (530 control individuals and 1407 subjects with Parkinson disease) from the International Parkinson's Disease Genomics Consortium (IPDGC) study: $3/530=0.0056$; $7/1407=0.005$, indicating that this observation is reliable. Considering only the variants predicted "possibly or probably damaging" by Polyphen-2, and the regions of *HCN1* that are sufficiently covered by exome sequencing *i.e.* (excluding positions c.1 to c.239, insufficiently covered), the number of heterozygotes in the ESP, PD and control populations is respectively 20, 1 and 0. These numbers are significantly lower than the number of *HCN1* damaging missense variants found in epileptic patients (*i.e.* 5/196, $p=0.00067$, $p=0.0001$ and $p=0.001$; Exact Fisher test).

Note that one PD patient has a *HCN1* nonsense mutation, further supporting the hypothesis that haploinsufficiency of *HCN1* does not cause EIEE.

Several missense variants present in these control populations are comparable, in terms of predictions, to the mutations identified in patients with EIEE. The existence of apparently or even well-characterized deleterious mutations in individuals from the ESP population is not specific of *HCN1* and is observed for other genes, in particular those involved in human epilepsies. For example, 51 different missense variants predicted to be deleterious are present in *SCN1A* in EVS, including the R1596C mutation in one individual⁴⁸. These observations have several possible grounds: 1) the clinical status of individuals included in the ESP population, in particular the occurrence of epilepsy in subjects with possibly deleterious variants, is unavailable; 2) the presence of the variants/mutations has not been validated and some of these variants might be false-positives or mosaic (*i.e.* present in the blood but not in the brain); 3) rare subjects might have constitutive deleterious mutations without expressing any symptom, possibly due to genetic buffering or other mechanisms.

- 23. Dibbens, L.M. et al. Augmented currents of an HCN2 variant in patients with febrile seizure syndromes. *Ann Neurol* 67, 542-6 (2010).
- 24. Tang, B., Sander, T., Craven, K.B., Hempelmann, A. & Escayg, A. Mutation analysis of the hyperpolarization-activated cyclic nucleotide-gated channels HCN1 and HCN2 in idiopathic generalized epilepsy. *Neurobiol Dis* 29, 59-70 (2008).
- 48. Cherepanova N.S., Leslie E., Ferguson P.J., Bamshad M.J. & Bassuk A.G. Presence of epilepsy-associated variants in large exome databases. *J Neurogenet* 27, 1-4 (2013).

Study	platform	CNV detection	population	Sample	DNA source	Genome version	Chr	CNV type	Gene	Number of ind	start	end	length	Localization/effect on HCN1	Phenotype
Itsara et al, 2009	Illumina 650Y	HMM	hgdp	HGDP01238	lymphoblastoid cell lines	Hg19	5	Del	HCN1	1	45339429	45445657	106228	encompasses exons 4 and 5	control subject
Itsara et al, 2009	Illumina 550K	HMM	NINDS-317+240	222	lymphoblastoid cell lines	Hg19	5	Del	HCN1	1	45361672	45506180	144508	encompasses exons 3 to 5	control subject
Itsara et al, 2009	Illumina 317K	HMM	parc-prince	X	peripheral blood	Hg19	5	Del	HCN1	1	45361672	46322869	961197	encompasses exons 1 to 5	control subject
Itsara et al, 2009	Illumina 550K	HMM	NINDS-550K	1780862470_A	lymphoblastoid cell lines	Hg19	5	Del	HCN1	1	45400632	45492834	92202	encompasses exon 3	control subject
Itsara et al, 2009	Illumina 317K	HMM	parc-prince	X	peripheral blood	Hg19	5	Del	HCN1	1	45400632	45506180	105548	encompasses exon 3	control subject
Itsara et al, 2009	Illumina 317K	HMM	parc-prince	X	peripheral blood	Hg19	5	Dup	HCN1	1	45442078	46264090	822012	encompasses exons 1 to 3	control subject
Pinto et al, 2011	Illumina 1M	PCNV	5 healthy subjects	NA10851	lymphoblastoid cell lines	Hg19	5	Del	HCN1	1	45363063	45383084	20022	in intron 4	control subject
Pinto et al, 2011	Illumina 1M	PCNV	5 healthy subjects	NA10851	lymphoblastoid cell lines	Hg19	5	Del	HCN1	1	45363063	45373943	10881	in intron 4	control subject
Pinto et al, 2011	Illumina 1M	PCNV	5 healthy subjects	NA15510	lymphoblastoid cell lines	Hg19	5	Del	HCN1	1	45363063	45383084	20022	in intron 4	control subject
Pinto et al, 2011	Illumina 1M	QSNP	5 healthy subjects	NA15510	lymphoblastoid cell lines	Hg19	5	Del	HCN1	1	45363063	45406321	43259	encompasses exon 4	control subject
Pinto et al, 2011	Illumina 1M	cnvPart	5 healthy subjects	NA18517	lymphoblastoid cell lines	Hg19	5	Del	HCN1	1	45363063	45409900	46838	encompasses exon 4	control subject
Pinto et al, 2011	Illumina 1M	PCNV	5 healthy subjects	NA18517	lymphoblastoid cell lines	Hg19	5	Del	HCN1	1	45366788	45378207	11420	in intron 4	control subject
Pinto et al, 2011	Illumina 1M	PCNV	5 healthy subjects	NA18517	lymphoblastoid cell lines	Hg19	5	Del	HCN1	1	45363063	45390738	27676	in intron 4	control subject
Pinto et al, 2011	Illumina 1M	PCNV	5 healthy subjects	NA18980	lymphoblastoid cell lines	Hg19	5	Del	HCN1	1	45363063	45409900	46838	encompasses exon 4	control subject

Cooper et al, 2011	CGH	HMM	15,767 children with ID	ND	peripheral blood	Hg19	5	Del	HCN1	3	NA	NA	NA	encompassing coding sequences: 13	Individuals with ID or DD +/- craniofacial defects (n=1)
Cooper et al, 2011	Illumina SNP arrays	HMM	8,329 control subjects	ND	peripheral blood	Hg19	5	Del	HCN1	13	NA	NA	NA		control subjects
Cooper et al, 2011	CGH	HMM	15,767 children with ID	ND	peripheral blood	Hg19	5	Dup	HCN1	9	NA	NA	NA	encompassing coding sequences: 5	Individuals with ID or DD and ASD (n=1) or craniofacial defects (n=4)
Cooper et al, 2011	Illumina SNP arrays	HMM	8,329 control subjects	ND	peripheral blood	Hg19	5	Dup	HCN1	5	NA	NA	NA		control subjects
Nava et al, 2013	Illumina SNP arrays	cnvPart	194 subjects with ASD	PSL_10744	peripheral blood	Hg19	5	Del	HCN1	1	NA	NA	NA	encompasses exon 4	Individual with ID and ASD

Supplementary Table 3 Copy number variants (CNVs) encompassing *HCN1* reported in the literature.

NA: unavailable

HCN1-ex1_F1	TACCCCTCTGGCTACGTGTC
HCN1-ex1_R1	CGTCCACCTTGAAGCACAC
HCN1-ex1_F2	GTCTAACAGCCGGACGAT
HCN1-ex1_R2	CGGAGGGAGAATTGTTGAC
HCN1-ex1_F3	TTCATGCAGAGGCAGTTCAC
HCN1-ex1_R3	GAGTGGAGCCTGCTTAGCC
HCN1-ex2_F1	GGGGGATAGGCTGGTTATTT
HCN1-ex2_R1	GGATGAGATGAAGTCAACCACA
HCN1-ex2_F2	GGACCCCAAAGTGATCAAGA
HCN1-ex2_R2	CATTGCACAGTTGTTATTGTAAG
HCN1-ex3_F	TGCTTACGCTACACAAACATCAA
HCN1-ex3_R	TTTGGCACACGTTGAAAA
HCN1-ex4_F	GCCATCCTAATGGCTCAGTC
HCN1-ex4_R	CTGGTTAAAGACATTGGCGATA
HCN1-ex5_F	TGATTCTGATACACCTAACATG
HCN1-ex5_R	AGGTTTTCTTAGAGTAACGTGGA
HCN1-ex6_F1	TTCAGCATGTTTCTTCAGA
HCN1-ex6_R1	TTTACCCACGGCTCCTTC
HCN1-ex6_F2	CGGAAACTGGTGGCTACAAT
HCN1-ex6_R2	CTGACATGCTGACATCTCAA
HCN1-ex7_F	TCAAACAAGTCATTCTTCTTG
HCN1-ex7_R	ATGAGTCACCACTCCCCACT
HCN1-ex8_F1	GCGTTGTCATCAGTCATTGG
HCN1-ex8_R1	TGGAGATTGTGTCCTCATGC
HCN1-ex8_F2	TGACAACCTGAATTCCACA
HCN1-ex8_R2	GAUTGCTGTACCTGCTGCTG
HCN1-ex8_F3	CCGCTCGAACTTCCACTATG
HCN1-ex8_R3	TCACGGGTTGAGGGATGG
HCN1-ex8_F4	CTCTGATTCCAGACCTCATCC
HCN1-ex8_R4	TGAGAGTATTCTTGCTTGACA

Supplementary Table 4 Primers used to amplify the coding regions of *HCN1*.

Supplementary Note Full alignments of HCN1 orthologous and paralogous sequences.

(a)

HCN1_HUMAN	MEGGGKPNSSSNSRDDGSVFPAKASATGAGPAAAEKRLGTPPGGGGAGAKEHGNVCFK
HCN1_MACAQUE	MEGGGKPNSSSNSRDDGSVFPAKASATGAGPAAAEKRLGTPPGGGGAGAKEHGNVCFK
HCN1_ORANGUTAN	MEGGGKPNSSSNSRDDGSVFPAKASATGAGPAAAEKRLGTPPGGGGAGAKEHGNVCFK
HCN1_MARMOSET	MEGGGKSNSSSNSRDDGSVFPAKASATGAGPAAAEKRLGTPPGGGGAGAKEHGNVCFK
HCN1_MOUSE	MEGGGKPNSASNSRDDGSVFP SKAPATGP--VAADKRLGTPPGGAAGKEHGNVCFK
HCN1_RAT	MEGGGKPNSASNSRDDGSVYPSKAPATGP--AAADKRLGTPPGGAAGKEHGNVCFK
HCN1_SQUIRREL	-----XCFKVD
HCN1_HORSE	-----
HCN1_COW	MEGGGKPNSSSNSRDDGSVFP TKAPATGAGPAAAEKRLGTPPGGGGTGAKEHGNVCFK
HCN1_GALAGO	MEGGGKPNSSSNSRDDGSVFSAKAPAASAGPAGAECRKGTPPGGGGAGAKEHGNVCFK
HCN1_DOG	MEAGGKPNSASNSRDDGSSAFPGKAPATGAGPAAAEKRLGTPPGGGGAGAKELGNVCFK
HCN1_PANDA	-----
HCN1_RABIT	-----
HCN1_PLATYPUS	-----
HCN1_BIRD	-----GGGSGGVKEHGNVCFK
HCN1_CHICKEN	-----MEGGKRSSSPGSRDEGSANA FPGKQATPVEKAQSSPGGGAKEHGNVCFK
HCN1_ANOLE	-----MEGSKPSSSPGSREDGSPGANACFQGKAEKAPGSPGASGSLKEHANSVCFK
HCN1_FROG	-----LPSMESKFNSSTNSSRDDGNNVLQGKAESLTASTSSVKEHGNVCFK
HCN1_PIG	-----MATASSPPRRPRRARGRQRPRS AWPARRGAAGPARRS
HCN1_TILAPIA	-----MEDKSNSFSSNKE-EKADGNVFQRQDSIQKNNTGSQNMK--DHGNSVGFK
HCN1_PLATYFISH	-----MEDKSNSFSSNKE-EKADGNVFQRQDSIQKNNTGSQNTK--DHGNSVGFK
HCN1_TETRAODON	-----GSQNTK--EHSNSVGFK
HCN1_TROUT	-----MEDKSNSFSSNKEGEKADGNVFQRQDSIQKNNMGSQNMKGGDHGNSVGFK
HCN1_HUMAN	VDGGGGGGGGGGGG--GEEPAGGFEDAEGPQQYGFMRQFTSMLQPGVNKFSLRMFGSQK
HCN1_MACAQUE	VDGGGGGGG-----EEPAGGFEDAEGPQQYGFMRQFTSMLQPGVNKFSLRMFGSQK
HCN1_ORANGUTAN	VDGGGGGEE-----PAGGFEDAEGPQQYGFMRQFTSMLQPGVNKFSLRMFGSQK
HCN1_MARMOSET	VDGGGGGGGGGG--EEPAGGFEDAEGPQQYGFMRQFTSMLQPGVNKFSLRMFGSQK
HCN1_MOUSE	VDGGG-----GEEPAGSFEDAEGPQQYGFMRQFTSMLQPGVNKFSLRMFGSQK
HCN1_RAT	VDGGG-----GEEPAGSFEDAEGPQQYGFMRQFTSMLQPGVNKFSLRMFGSQK
HCN1_SQUIRREL	GGGGG-----GEEPAGSFEDAEGPQQYGFMRQFTSMLQPGVNKFSLRMFGSQK
HCN1_HORSE	-----
HCN1_COW	VDGGGGGE-----ESAGGFEDAEGPQQYGFMRQFTSMLQPGVNKFSLRMFGSQK
HCN1_GALAGO	VDGGGGGAE-----ESAGGFEDAEGPQQYGFMRQFTSMLQPGVNKFSLRMFGSQK
HCN1_DOG	VDGGGAGEEE-----PAGGFEDAEGPQQYGFMRQFTSMLQPGVNKFSLRMFGSQK
HCN1_PANDA	-----GFMQRQFTSMLQPGVNKFSLRMFGSQK
HCN1_RABIT	-----MATASSPPR-RP RARGLEDAEGPQQYGFMRQFTSMLQPGVNKFSLRMFGSQK
HCN1_PLATYPUS	-----
HCN1_BIRD	-----AVGFEDAEGPQQYGFMRQFTSMLQPGVNKFSLRMFGSQK
HCN1_CHICKEN	-----VVGFEDAEGPQQYGFMRQFTSMLQPGVNKFSLRMFGSQK
HCN1_ANOLE	-----VDGSGAAGEEPVAGLDDPDAARRQQQQQQQYGFMRQFTSMLQPGVNKFSLRMFGSQK
HCN1_FROG	-----TDAADDPVVG-----FEDAEGPSRPHGFMQRQFGSMLQPGVNKFSLRMFGSQK
HCN1_PIG	-----TATPCASRWTA AAAVAARSRP GASRTRRGPGGSTASC SGS HLYAAAWGQQILPPHVWEPE
HCN1_TILAPIA	-----GEREETMVG-----FDDLEGASRQHGFMRQFGAMMQPGVNKFSLRMFGSQK
HCN1_PLATYFISH	-----GEREAMVG-----FDDLDGASRQHGFMRQFGAMMQPGVNKFSLRMFGSQK
HCN1_TETRAODON	-----GEREAMVG-----FDDLEGASRQHGFMRQFGAMMQPGVNKFSLRMFGSQK
HCN1_TROUT	-----GDREALVG-----FDDIDGSGNRHGFMRQFGAMMQPGVNKFSLRMFGSQK
HCN1_HUMAN	A VEKEQERVKTAGFWI IHPYSDFRYWDLIMLIMMVGNLVIIPVGITFFTEQTTTPWIIF
HCN1_MACAQUE	A VEKEQERVKTAGFWI IHPYSDFRYWDLIMLIMMVGNLVIIPVGITFFTEQTTTPWIIF
HCN1_ORANGUTAN	A VEKEQERVKTAGFWI IHPYSDFRYWDLIMLIMMVGNLVIIPVGITFFTEQTTTPWIIF
HCN1_MARMOSET	A VEKEQERVKTAGFWI IHPYSDFRYWDLIMLIMMVGNLVIIPVGITFFTEQTTTPWIIF
HCN1_MOUSE	A VEKEQERVKTAGFWI IHPYSDFRYWDLIMLIMMVGNLVIIPVGITFFTEQTTTPWIIF
HCN1_RAT	A VEKEQERVKTAGFWI IHPYSDFRYWDLIMLIMMVGNLVIIPVGITFFTEQTTTPWIIF
HCN1_SQUIRREL	A VEKEQERVKTAGFWI IHPYSDFRYWDLIMLIMMVGNLVIIPVGITFFTEQTTTPWIIF
HCN1_HORSE	-----RFYWDLIMLIMMVGNLVIIPVGITFFTEQTTTPWIIF
HCN1_COW	A VEKEQERVKTAGFWI IHPYSDFRYWDLIMLIMMVGNLVIIPVGITFFTEQTTTPWIIF
HCN1_GALAGO	A VEKEQERVKTAGFWI IHPYSDFRYWDLIMLIMMVGNLVIIPVGITFFTEQTTTPWIIF
HCN1_DOG	A VEKEQERVKTAGFWI IHPYSDFRYWDLIMLIMMVGNLVIIPVGITFFTEQTTTPWIIF
HCN1_PANDA	A VEKEQERVKTAGFWI IHPYSDFRYWDLIMLIMMVGNLVIIPVGITFFTEQTTTPWIIF
HCN1_RABIT	A VEKEQERVKTAGFWI IHPYSDFRYWDLIMLIMMVGNLVIIPVGITFFTEQTTTPWIIF
HCN1_PLATYPUS	-----MLIMMVGNLVIIPVGITFFTEQTTTPWIIF
HCN1_BIRD	A VEKEQERVKTAGFWI IHPYSDFRYWDLIMLIMMVGNLVIIPVGITFFTEQTTTPWIIF
HCN1_CHICKEN	A VEKEQERVKTAGFWI IHPYSDFRYWDLIMLIMMVGNLVIIPVGITFFTEQTTTPWIIF
HCN1_ANOLE	A VEKEQERVKTAGFWI IHPYSDFRYWDLIMLIMMVGNLVIIPVGITFFTEQTTTPWIIF
HCN1_FROG	A VEKEQERVKTAGFWI IHPYSDFRYWDLIMLIMMVGNLVIIPVGITFFTEQTTTPWIIF
HCN1_PIG	GGEKEQERVKTAGFWI IHPYSDFRYWDLIMLIMMVGNLVIIPVGITFFTEQTTTPWIIF
HCN1_TILAPIA	A VEKEQERVQTAGFWI IHPYSDFRYWDLIMLIMMMGNLIIIPVGITFFSEQTTTTWLVF

HCN1_PLATYFISH FNLIQGMLLLCHWDGCLQYLVPLLQDFPPDCWVSLNGMVNVSGKQYSYALFKAMSHMLC
 HCN1_TETRAODON FNLIQGMLLLCHWDGCLQYLVP-LQDFPPDCWVSLNGMVNVSGKQYSYALFKAMSHMLC
 HCN1_TROUT FNLIQGMLLLCHWDGCLQFLVPLLQDFPQDCWVSLNGMVNDSWGKQYSYALFKAMSHMLC
 ****:***:***:***:***:***:***:***:***:***:***:***:***:***:

 HCN1_HUMAN IGYGAQAPVSMSDLWITMLSMIVGATCYAMFVGHATALIQSLD---SSRRQYQEKYKQV
 HCN1_MACAQUE IGYGAQAPVSMSDLWITMLSMIVGATCYAMFVGHATALIQSLD---SSRRQYQEKYKQV
 HCN1_ORANGUTAN IGYGAQAPVSMSDLWITMLSMIVGATCYAMFVGHATALIQSLD---SSRRQYQEKYKQV
 HCN1_MARMOSET IGYGAQAPVSMSDLWITMLSMIVGATCYAMFVGHATALIQSLD---SSRRQYQEKYKQV
 HCN1_MOUSE IGYGAQAPVSMSDLWITMLSMIVGATCYAMFVGHATALIQSLD---SSRRQYQEKYKQV
 HCN1_RAT IGYGAQAPVSMSDLWITMLSMIVGATCYAMFVGHATALIQSLD---SSRRQYQEKYKQV
 HCN1_SQUIRREL IGYGAQAPVSMSDLWITMLSMIVGATCYAMFVGHATALIQSLD---SSRRQYQEKYKQV
 HCN1_HORSE IGYGAQAPVSMSDLWITMLSMIVGATCYAMFVGHATALIQSLD---SSRRQYQEKYKQV
 HCN1_COW IGYGAQAPVSMSDLWITMLSMIVGATCYAMFVGHATALIQSLD---SSRRQYQEKYKQV
 HCN1_GALAGO IGYGAQAPVSMSDLWITMLSMIVGATCYAMFVGHATALIQSLD---SSRRQYQEKYKQV
 HCN1_DOG IGYGAQAPVSMSDLWITMLSMIVGATCYAMFVGHATALIQSLD---SSRRQYQEKYKQV
 HCN1_PANDA IGYGAQAPVSMSDLWITMLSMIVGATCYAMFVGHATALIQSLD---SSRRQYQEKYKQV
 HCN1_RABBIT IGYGAQAPVSMSDLWITMLSMIVGATCYAMFVGHATALIQSLD---SSRRQYQEKYKQV
 HCN1_PLATYFUS VKCLLPASVSEGSQLLTL SALHTPPFFLYDSSFLGHSGWLNLENSEKEFNIKEYKQV
 HCN1_BIRD IGYGARAPVSMSDLWITMLSMIVGATCYAMFVGHATALIQSLD---SSRRQYQEKYKQV
 HCN1_CHICKEN IGYGARAPVSMSDLWITMLSMIVGATCYAMFVGHATALIQSLD---SSRRQYQEKYKQV
 HCN1_ANOLE IGYGARAPVSMSDLWITMLSMIVGATCYAMFVGHATALIQSLD---SSRRQYQEKYKQV
 HCN1_FROG IGYGARAPVSMSDLWITMLSMIVGATCYAMFVGHATALIQSLD---SSRRQYQEKYKQV
 HCN1_PIG IGYGARAPVSMSDLWITMLSMIVGATCYAMFVGHATALIQSLD---SSRRQYQEKYKQV
 HCN1_TILAPIA IGYGARAPVSMSDLWITMLSMIVGATCYAMFVGHATALIQSLD---SSRRQYQEKYKQV
 HCN1_PLATYFISH IGYGARAPVSMSDLWITMLSMIVGATCYAMFVGHATALIQSLD---SSRRQYQEKYKQV
 HCN1_TETRAODON IGYGARAPVSMSDLWITMLSMIVGATCYAMFVGHATALIQSLD---SSRRQYQEKYKQV
 HCN1_TROUT : *.*. .: :* * : .. : .. *.*. *. : :****:

 HCN1_HUMAN EQYMSFHKLPADMQRQIHDYYEHRYQKGIFDEENILNELNDPLREEIVNFNCRKLVATMP
 HCN1_MACAQUE EQYMSFHKLPADMQRQIHDYYEHRYQKGIFDEENILNELNDPLREEIVNFNCRKLVATMP
 HCN1_ORANGUTAN EQYMSFHKLPADMQRQIHDYYEHRYQKGIFDEENILNELNDPLREEIVNFNCRKLVATMP
 HCN1_MARMOSET EQYMSFHKLPADMQRQIHDYYEHRYQKGIFDEENILSELNDPLREEIVNFNCRKLVATMP
 HCN1_MOUSE EQYMSFHKLPADMQRQIHDYYEHRYQKGIFDEENILSELNDPLREEIVNFNCRKLVATMP
 HCN1_RAT EQYMSFHKLPADMQRQIHDYYEHRYQKGIFDEENILSELNDPLREEIVNFNCRKLVATMP
 HCN1_SQUIRREL EQYMSFHKLPADMQRQIHDYYEHRYQKGIFDEENILSELNDPLREEIVNFNCRKLVATMP
 HCN1_HORSE EQYMSFHKLPADMQRQIHDYYEHRYQKGIFDEENILSELNDPLREEIVNFNCRKLVATMP
 HCN1_COW EQYMSFHKLPADMQRQIHDYYEHRYQKGIFDEENILSELNDPLREEIVNFNCRKLVATMP
 HCN1_GALAGO EQYMSFHKLPADMQRQIHDYYEHRYQKGIFDEENILSELNDPLREEIVNFNCRKLVATMP
 HCN1_DOG EQYMSFHKLPADMQRQIHDYYEHRYQKGIFDEENILSELNDPLREEIVNFNCRKLVATMP
 HCN1_PANDA EQYMSFHKLPADMQRQIHDYYEHRYQKGIFDEENILSELNDPLREEIVNFNCRKLVATMP
 HCN1_RABBIT EQYMSFHKLPADMQRQIHDYYEHRYQKGIFDEENILSELNDPLREEIVNFNCRKLVATMP
 HCN1_PLATYFUS EQYMSFHKLPADMQRQIHDYYEHRYQKGIFDEENILSELNDPLREEIVNFNCRKLVATMP
 HCN1_BIRD EQYMSFHKLPADMQRQIHDYYEHRYQKGIFDEENILSELNDPLREEIVNFNCRKLVATMP
 HCN1_CHICKEN EQYMSFHKLPADMQRQIHDYYEHRYQKGIFDEENILSELNDPLREEIVNFNCRKLVATMP
 HCN1_ANOLE EQYMSFHKLPADMQRQIHDYYEHRYQKGIFDEENILSELNDPLREEIVNFNCRKLVATMP
 HCN1_FROG EQYMSFHKLPADMQRQIHDYYEHRYQKGIFDEENILSELNDPLREEIVNFNCRKLVATMP
 HCN1_PIG EQYMSFHKLPADMQRQIHDYYEHRYQKGIFDEENILSELNDPLREEIVNFNCRKLVATMP
 HCN1_TILAPIA EQYMSFHKLPADMQRQIHDYYEHRYQKGIFDEENILSELNDPLREEIVNFNCRKLVATMP
 HCN1_PLATYFISH EQYMSFHKLPADMQRQIHDYYEHRYQKGIFDEENILSELNDPLREEIVNFNCRKLVATMP
 HCN1_TETRAODON EQYMSFHKLPADMQRQIHDYYEHRYQKGIFDEENILSELNDPLREEIVNFNCRKLVATMP
 HCN1_TROUT *****:*****:*****:*****:

 HCN1_HUMAN LFANADPNFTAMLSKLRFEVFQPGDYIIREGAVGKKMYFIQHGVAGVITKSSKEMKLTD
 HCN1_MACAQUE LFANADPNFTAMLSKLRFEVFQPGDYIIREGAVGKKMYFIQHGVAGVITKSSKEMKLTD
 HCN1_ORANGUTAN LFANADPNFTAMLSKLRFEVFQPGDYIIREGAVGKKMYFIQHGVAGVITKSSKEMKLTD
 HCN1_MARMOSET LFANADPNFTAMLSKLRFEVFQPGDYIIREGAVGKKMYFIQHGVAGVITKSSKEMKLTD
 HCN1_MOUSE LFANADPNFTAMLSKLRFEVFQPGDYIIREGAVGKKMYFIQHGVAGVITKSSKEMKLTD
 HCN1_RAT LFANADPNFTAMLSKLRFEVFQPGDYIIREGAVGKKMYFIQHGVAGVITKSSKEMKLTD
 HCN1_SQUIRREL LFANADPNFTAMLSKLRFEVFQPGDYIIREGAVGKKMYFIQHGVAGVITKSSKEMKLTD
 HCN1_HORSE LFANADPNFTAMLSKLRFEVFQPGDYIIREGAVGKKMYFIQHGVAGVITKSSKEMKLTD
 HCN1_COW LFANADPNFTAMLSKLRFEVFQPGDYIIREGAVGKKMYFIQHGVAGVITKSSKEMKLTD
 HCN1_GALAGO LFANADPNFTAMLSKLRFEVFQPGDYIIREGAVGKKMYFIQHGVAGVITKSSKEMKLTD
 HCN1_DOG LFANADPNFTAMLSKLRFEVFQPGDYIIREGAVGKKMYFIQHGVAGVITKSSKEMKLTD
 HCN1_PANDA LFANADPNFTAMLSKLRFEVFQPGDYIIREGAVGKKMYFIQHGVAGVITKSSKEMKLTD
 HCN1_RABBIT LFANADPNFTAMLSKLRFEVFQPGDYIIREGAVGKKMYFIQHGVAGVITKSSKEMKLTD
 HCN1_PLATYFUS LFANADPNFTAMLSKLRFEVFQPGDYIIREGAVGKKMYFIQHGVAGVITKSSKEMKLTD
 HCN1_BIRD LFANADPNFTAMLSKLRFEVFQPGDYIIREGAVGKKMYFIQHGVAGVITKSSKEMKLTD
 HCN1_CHICKEN LFANADPNFTAMLSKLRFEVFQPGDYIIREGAVGKKMYFIQHGVAGVITKSNKELKLTD
 HCN1_ANOLE LFANADPNFTAMLSKLRFEVFQPGDYIIREGAVGKKMYFIQHGVAGVITKSNKELKLTD
 HCN1_FROG LFANADPNFTAMLSKLRFEVFQPGDYIIREGAVGKKMYFIQHGVAGVITKSNKELKLTD
 HCN1_PIG LFANADPNFTAMLSKLRFEVFQPGDYIIREGAVGKKMYFIQHGVAGVITKSNKELKLTD
 HCN1_TILAPIA LFANADPNFTAMLSKLRFEVFQPGDYIIREGAVGKKMYFIQHGVAGVITKSNKELKLTD

HCN1_PLATYFISH LFANADPNFVTGMLSKLKFEVQPNDYIIREGTVGKKMYFIQHGVSVITKFNKEMKLTD
 HCN1_TETRAODON LFANADPNFVTGMLSKLKFEVQPNDYIIREGTVGKKMYFIQHGVASVITKSNKEMKLTD
 HCN1_TROUT LFANADPNFVTGMLSKLKFEVQPNDYIIREGTVGKKMYFIQHGVASVITKLNKEMKLTD
 ****.*****:*****:*****:*****:*****:*****:*****:*****:*****:

 HCN1_HUMAN GSYFG-EICLLTKGRRRTASVRADTYCRLYSLSDVNNEVLEYPMMRRAFETVAIDRLDR
 HCN1_MACAQUE GSYFG-EICLLTKGRRRTASVRADTYCRLYSLSDVNNEVLEYPMMRRAFETVAIDRLDR
 HCN1_ORANGUTAN GSYFG-EICLLTKGRRRTASVRADTYCRLYSLSDVNNEVLEYPMMRRAFETVAIDRLDR
 HCN1_MARMOSET GSYFG-EICLLTKGRRRTASVRADTYCRLYSLSDVNNEVLEYPMMRRAFETVAIDRLDR
 HCN1_MOUSE GSYFG-EICLLTKGRRRTASVRADTYCRLYSLSDVNNEVLEYPMMRRAFETVAIDRLDR
 HCN1_RAT GSYFG-EICLLTKGRRRTASVRADTYCRLYSLSDVNNEVLEYPMMRRAFETVAIDRLDR
 HCN1_SQUIRREL GSYFG-EICLLTKGRRRTASVRADTYCRLYSLSDVNNEVLEYPMMRRAFETVAIDRLDR
 HCN1_HORSE GSYFG-EICLLTKGRRRTASVRADTYCRLYSLSDVNNEVLEYPMMRRAFETVAIDRLDR
 HCN1_COW GSYFG-EICLLTKGRRRTASVRADTYCRLYSLSDVNNEVLEYPMMRRAFETVAIDRLDR
 HCN1_GALAGO GSYFG-EICLLTKGRRRTASVRADTYCRLYSLSDVNNEVLEYPMMRRAFETVAIDRLDR
 HCN1_DOG GSYFG-EICLLTKGRRRTASVRADTYCRLYSLSDVNNEVLEYPMMRRAFETVAIDRLDR
 HCN1_PANDA GSYFG-EICLLTKGRRRTASVRADTYCRLYSLSDVNNEVLEYPMMRRAFETVAIDRLDR
 HCN1_RABBIT GSYFG-EICLLTKGRRRTASVRADTYCRLYSLSDVNNEVLEYPMMRRAFETVAIDRLDR
 HCN1_PLATYFISH GSYFGAEIICLLTKGRRRTASVRADTYCRLYSLSDVNNEVLEYPMMRRAFETVAIDRLDR
 HCN1_BIRD GSYFG-EICLLTKGRRRTASVRADTYCRLYSLSDVNNEVLEYPMMRRAFETVAIDRLDR
 HCN1_CHICKEN GSYFG-EICLLTKGRRRTASVRADTYCRLYSLSDVNNEVLEYPMMRRAFETVAIDRLDR
 HCN1_ANOLE GSYFG-EICLLTKGRRRTASVRADTYCRLYSLSDVNNEVLEYPMMRRAFETVAIDRLDR
 HCN1_FROG GSYFG-EICLLTKGRRRTASVRADTYCRLYSLSDVNNEVLEYPMMRRAFETVAIDRLDR
 HCN1_PIG GSYFG-EICLLTKGRRRTASVRADTYCRLYSLSDVNNEVLEYPMMRRAFETVAIDRLDR
 HCN1_TILAPIA GSYFG-EICLLTKGRRRTASVRADTYCRLYSLSDVNNEVLEYPMMRRAFETVAIDRLDR
 HCN1_PLATYFISH GSYFG-EICLLTKGRRRTASVRADTYCRLYSLSDVNNEVLEYPMMRRAFETVAIDRLDR
 HCN1_TETRAODON GSYFG-EICLLTKGRRRTASVRADTYCRLYSLSDVNNEVLEYPMMRRAFETVAIDRLDR
 HCN1_TROUT ****.*****:*****:*****:*****:*****:

 HCN1_HUMAN IGKKNSILLQKFQKDLNTGVFNNQENEILKQIVKHREMVQAIP-----
 HCN1_MACAQUE IGKKNSILLQKFQKDLNTGVFNNQENEILKQIVKHREMVQAIP-----
 HCN1_ORANGUTAN IGKKNSILLQKFQKDLNTGVFNNQENEILKQIVKHREMVQAIP-----
 HCN1_MARMOSET IGKKNSILLQKFQKDLNTGVFNNQENEILKQIVKHREMVQAIP-----
 HCN1_MOUSE IGKKNSILLQKFQKDLNTGVFNNQENEILKQIVKHREMVQAIPPP-----
 HCN1_RAT IGKKNSILLQKFQKDLNTGVFNNQENEILKQIVKHREMVQAIP-----
 HCN1_SQUIRREL IGKKNSILLQKFQKDLNTGVFNNQENEILKQIVKHREMVQAIP-----
 HCN1_HORSE IGKKNSILLQKFQKDLNTGVFNNQENEILKQIVKHREMVQAIP-----
 HCN1_COW IGKKNSILLQKFQKDLNTGVFNNQENEILKQIVKHREMVQAIP-----
 HCN1_GALAGO IGKKNSILLQKFQKDLNTGVFNNQENEILKQIVKHREMVQAIP-----
 HCN1_DOG IGKKNSILLQKFQKDLNTGVFNNQENEILKQIVKHREMVQAIP-----
 HCN1_PANDA IGKKNSILLQKFQKDLNTGVFNNQENEILKQIVKHREMVQAIP-----
 HCN1_RABBIT IGKKNSILLQKFQKDLNTGVFNNQENEILKQIVKHREMVQAIP-----
 HCN1_PLATYFISH IGKKNSILLQKFQKDLNTGVFNNQENEILKQIVKHREMVQQTAP-----
 HCN1_BIRD IGKKNSILLQKFQKDLNTGVFNNQENEILKQIVKHREMVQTIAP-----
 HCN1_CHICKEN IGKKNSILLQKFQKDLNTGVFNNQENEILKQIVKHREMVQTIAP-----
 HCN1_ANOLE IGKKNSILLQKFQKDLNTGVFNNQEQEILKQIVKHREMVQTVGP-----
 HCN1_FROG IGKKNSILLQKFQKDLNTGVFNNQEQEILKQIVKHREMVQTVGP-----
 HCN1_PIG IGKKNSILLQKFQKDLNTGVFNNQEQEILKQIVKHREMVQTVGP-----
 HCN1_TILAPIA IGKKNSILLQKFQKDLNAGVFNTQENEELLQKIIRQDREMVMVDRKQSVD-----
 HCN1_PLATYFISH IGKKNSILLQKFQKDLNAGVFNTQENEILKQIIRQDREMVMVDRKQSVD-----
 HCN1_TETRAODON IGKKNSILLQKFQKDLNAGVFNTQENELMKQIIRQDR-----
 HCN1_TROUT IGKKNSILLQKFQKDLNAGVFNTQENEILKQIIRQDREMVMVDRKQSVTGMSVTGMSVT
 **. **:

 HCN1_HUMAN -----INYPQMTTLNSTSSTTTPTSRM
 HCN1_MACAQUE -----INYPQMTTLNSTSSTTTPTSRM
 HCN1_ORANGUTAN -----INYPQMTTLNSTSSTTTPTSRM
 HCN1_MARMOSET -----INYPQMTTLNSTPSTTTPTSRM
 HCN1_MOUSE -----INYPQMTALNCSTSSTTTPTSRM
 HCN1_RAT -----INYPQMTALNCSTSSTTTPTSRM
 HCN1_SQUIRREL -----INYPQMTALNSTSSTTTPTSRM
 HCN1_HORSE -----INYPQMTALNSTSSTTTPTSRM
 HCN1_COW -----INYPQMTALNSTSSTTTPTSRM
 HCN1_GALAGO -----INYPQMTALNSTSSTASTTTPTSRV
 HCN1_DOG -----INYPQMTALNSTSSTATPTCRA
 HCN1_PANDA -----INYPQMTALNSASSTTTPTSRM
 HCN1_RABBIT -----ISYPQMTALNSTSTATPTSRM
 HCN1_PLATYFUS -----ANYSQMPSLNSSASTTLQSSRL
 HCN1_BIRD -----VSLQQMPALN--SSTAA-SSRG
 HCN1_CHICKEN -----VSLQQMPALNSSSSTTS-SSRV
 HCN1_ANOLE -----VLLQQMPALN---SATASAM
 HCN1_FROG -----VSYQQLPALN--SSTSSSLRM
 HCN1_PIG -----
 HCN1_TILAPIA -----GMNSTPMMSGNSIINSPAQPFSTAFGTTQLQQSSVPLTYSASAIA

HCN1_PLATYFISH GMNSTPMMSGNSIINSPAQPYPYSTAFGAAQLQQSSVPMTYSASAIANASVARMLPVAAAAA
HCN1_TETRAODON -----EMLQQASAPMTYSASAIANASAARMLPVAAAAA
HCN1_TROUT GMNTTPISGNSIINSPAQPYPYTTALGNNFQQSATSLTYSASAVTAPSSAATARILPASA

HCN1_HUMAN RTQSPPVYTATSLSHSNLHSPLSPSTQTQPQPSAILSPCSYTTAVCSPPVQSPPLAA-RTFH
HCN1_MACAQUE RTQSPPVYTATSLSHSNLHSPLSPSTQTQPQPSAILSPCSYTTAVCSPPVQSPPLAA-RTFH
HCN1_ORANGUTAN RTQSPPVYTATSLSHSNLHSPLSPSTQTQPQPSAILSPCSYTTAVCSPPVQSPPLAA-RTFH
HCN1_MARMOSET RTQSPPVYTATSLSHSNLHSPLSPSTQTQPQPSAILSPCSYTTAVCSPPVQSPPLAA-RTFH
HCN1_MOUSE RTQSPPVYTATSLSHSNLHSPLSPSTQTQPQPSAILSPCSYTTAVCSPPVQSPPLAA-RTFH
HCN1_RAT RTQSPPVYTATSLSHSNLHSPLSPSTQTQPQPSAILSPCSYTTAVCSPPVQSPPLAA-RTFH
HCN1_SQUIRREL RTQSPPVYTATSLSHSNLHSPLSPSTQTQPQPSAILSPCSYTTAVCSPPVQSPPLAA-RTFH
HCN1_HORSE RTQSPPVYTATSLSHSNLHSPLSPSTQTQPQPSAILSPCSYTTAVCSPPVQSPPLAA-RTFH
HCN1_COW RTQSPPVYTATSLSHSNLHSPLSPSTQTQPQPSAILSPCSYTTAVCSPPVQSPPLAA-RTFH
HCN1_GALAGO RTQSPPVYTATSLSHSNLHSPLSPSTQTQPQPSAILSPCSYTTAVCSPPVQSPPLAA-RTFH
HCN1_DOG RTQSPPVYTATSLSHSNLHSPLSPSTQTQPQPSAILSPCSYTTAVCSPPVQSPPLAA-RTFH
HCN1_PANDA RTQSPPVYTATSLSHSNLHSPLSPSTQTQPQPSAILSPCSYTTAVCSPPVQSPPLAA-RTFH
HCN1_RABIT RTQSPPVYTATSLSHSNLHSPLSPSTQTQPQPSAILSPCSYTTAVCSPPVQSPPLAA-RTFH
HCN1_PLATYFUS RTQSPPVYTATSLSHSNLHSPLSPSTQTQPQPSAILSPCSYTTAVCSPPVQSPPLAA-RTFH
HCN1_BIRD RTQSPPVYSTSSLSHGNLHSPLSPSTQPQQAVILSPCSYTTAVCSPPVQSPPLAG-RTFQY
HCN1_CHICKEN RTQSPPVYTAGSLSHGNLHSPLSPSTQPQQAVILSPCSYTTAVCSPPVQSPPLAG-RTFQY
HCN1_ANOLE RTQSPPVYSMTSLSHGSLSNPTSTQPQQAAIFSPCSYSSAVCSPPVQSPFLAAGRFTQY
HCN1_FROG RTRSPPVYNANSLSHGNLQSPTPSPQTPQQAVVFSPPSFTSAACSPSVQSPLAG-RTFQY
HCN1_PIG AAAQGLYQTQSG---TLNSSQT---PLQQQGAIMSPCSFTAAMCSPPVQTP-LANRSFQY
HCN1_TILAPIA AVAQGGFPPTSSLSQVNLNSSQ---TALQQGAIMSPCSFTAAMCSPPVQTP-LASRSFQY
HCN1_PLATYFISH AAAQAGYPPPSLHSSLNSSLTNPQGALQQAAIMSPCSFTAAMCSPPVQTP-LANRSFQY
HCN1_TETRAODON QGVYPVPSVIHGNNLNSSPVPQTPLSLHQQGSIMSPVSFTTAVCSPPVQTPGLAGRSFQY
HCN1_TROUT

HCN1_HUMAN ASPTASQLSLMQQ-----QPOQQQVQQSQPPQTQ
HCN1_MACAQUE ASPTASQLSLMQQ-----QPOQQQVQQSQPPQTQ
HCN1_ORANGUTAN ASPTASQLSLMQQ-----QPOQQQVQQSQPPQTQ
HCN1_MARMOSET ASPTASQLSLMQQ-----QPOQQQVQQSQPPQTQ
HCN1_MOUSE ASPTASQLSLMQQ-----QPOQQQVQQSQPPQTQ
HCN1_RAT ASPTASQLSLMQQ-----QPOQQQVQQSQPPQTQ
HCN1_SQUIRREL ASPTASQLSLMQQ-----QPOQQQVQQSQPPQTQ
HCN1_HORSE ASPTASQLSLMQQ-----QPOQQQVQQSQPPQTQ
HCN1_COW ASPTASQLSLIQQ-----QOVOQOPPOPQ
HCN1_GALAGO ASPTASQLSLMQQ-----QLQSQPPPQT
HCN1_DOG ASPTASQLSLAQQPQP-----AQPPQPQPAQPAQPPQPQ
HCN1_PANDA ASPTASQLSLTQQQQ-----QQLQQPPPQT
HCN1_RABIT ASPTASQLSLMPQ-----QQQQPQAPQTQ
HCN1_PLATYFUS VSPTASQLSLMQQ-----Q
HCN1_BIRD ASPTASQLSLMQQQQ-----QQQQGGGGGGGGGG
HCN1_CHICKEN ASPTASQLSLMQQQ-----
HCN1_ANOLE ATPTASQLSLLQQ-----
HCN1_FROG SSLTASQLSLIQQQQ-----
HCN1_PIG ASPTASQLSLIQQPIA-----QPSLSTQQLSQQPAAPTA
HCN1_TILAPIA GSPTASQLSLIQQPIG-----QPSLPTQQQLGQQPAAS
HCN1_PLATYFISH GSRTASQLSLIQQPTG-----QPTLPTQQPP-----
HCN1_TETRAODON GSPTASQLSLIQQPLP-----TALPPQQPLPQPQPGGA

HCN1_HUMAN PQQSPSPQPQTP-----GSSTPKNEVKSTQALHNTNLREVRPLSASQPSLPHE
HCN1_MACAQUE PQQSPSPQPQTP-----GSSTPKNEVKSTQALHNTNLREVRPLSASQPSLPHE
HCN1_ORANGUTAN PQQSPSPQPQTP-----GSSTPKNEVKSTQALHNTNLREVRPLSASQPSLPHE
HCN1_MARMOSET PQQQSPQPQTP-----GSSTPKNEVKSTQALHNTNLREVRPLSASQPSLPHE
HCN1_MOUSE QQQQQQQQPQTP-----GSSTPKNEVKSTQALHNTNLREVRPLSASQPSLPHE
HCN1_RAT QQQQQQQQPQTP-----GSSTPKNEVKSTQALHNTNLREVRPLSASQPSLPHE
HCN1_SQUIRREL QQQPPQQQPQTP-----SSSTPKNEVKSTQALHNTNLREVRPLSASQPSLPHE
HCN1_HORSE PQQQQPQQQPQTP-----SSSTPKNDVHKSTQALHNTSLTRDVRPLSASQPSLPHE
HCN1_COW Q--PPQPPPQTP-----GSSTPKNEVKSTQALHNTSLTRDVRPLSASQPSLPHE
HCN1_GALAGO QQPPPPPPPQTP-----GSSTPKNEVKSTQALHNASLTREVRPLSASQPSLPHE
HCN1_DOG PPQPQPQPPQPPQPPQTPGGGSPRNDVHRSTQALHNASLTREVRPLSASQPSLPHE
HCN1_PANDA PPQPQPQPPQTP-----STSTPRNDVHRSTQALHNTSLTRDVRPLSASQPSLPHE
HCN1_RABIT PQQPPQQQPQTP-----GSATPKNEVHRSTQALPNTSLTRDVRPLSASQPSLPHE
HCN1_PLATYFUS QPPSQQQQPQPP-----PSSAQKNEVKSTQALHNTNLREARPLSASQPSLPHE
HCN1_BIRD GQQQQQAAQQP-----PGAAQKNEVKSTQALHNTNLREARPLSASQPSLPHE
HCN1_CHICKEN ---PQAPQLP-----PGTAPKNEVKSTQALHNTNLREARPLSASQPSLPHE
HCN1_ANOLE QQLQQQQQPQOP-----LQQMPSASQKSDVHKSTQALHNASLTREVRPLSASQPSLPHE
HCN1_FROG -----ASGASQIHEVHKSAQALANTNLREVRPLSASQPSLPHE
HCN1_PIG -----ATSSAAQQQQQQQQQASPQQQVPSQQRGD-IHKSTQALQSGSLSRDVRHLSASQPSLPHD
HCN1_TILAPIA

HCN1_PLATYFISH	TAAAAS-----AAQQQVPSPQRGD-IHKSTQALQSGSLSRDVRHLSASQPSLPHD
HCN1_TETRAODON	-----ASATASAPSPQRGD-IPKGQAQALQSGSLSRDVRHLSASQPSLPH
HCN1_TROUT	AASSATQQ-----PQQQQQVPSPQRSDSLHKASHALQSGSLSRDVRHLSASQPSLPHD

HCN1_HUMAN	VSTLISRPHPTVGESLASIPQPVTAVPGTGLQAGGRSTVPRVTLFRQMSSGAIPPNRGV
HCN1_MACAQUE	VSTLISRPHPTVGESLASIPQPVTAVPGTGLQAGGRSTVPRVTLFRQMSSGAIPPNRGV
HCN1_ORANGUTAN	VSTLISRPHPTVGESLASIPQPVTAVPGTGLQAGGRSTVPRVTLFRQMSSGAIPPNRGV
HCN1_MARMOSET	VSTLISRPHPTVGESLASIPQPVTAVPGTGLQAGGRSTVPRVTLFRQMSSGAIPPNRGV
HCN1_MOUSE	VSTLISRPHPTVGESLASIPQPVTAVPGTGLQAGGRSTVPRVTLFRQMSSGAIPPNRGV
HCN1_RAT	VSTMISRPHPTVGESLASIPQPVTAVHSTGLQAGSRSTVPRVTLFRQMSSGAIPPNRGV
HCN1_SQUIRREL	VSTLISRPHPTVGESLASIPQPVAAVHGTSQAGGRGTVPRVTLFRQMSSGAIPPNRGV
HCN1_HORSE	VSTLISRPHPTVGESLASIPQPVTAVHGTLQAGGRGTVPRVTLFRQMSSGAIPPNRGV
HCN1_COW	VSTLISRPHPTVGESLASIPQPVTAVHGGLQAGGRGTVPRVTLFRQMSSGAIPPNRGV
HCN1_GALAGO	VSTLISRPHPTVGESLASIPQPVTAVHGGLQAGGRGTVPRVTLFRQMSSGAIPPNRGV
HCN1_DOG	VATLMSRPHPTVGESLASIPQPVTAVHGPGLQAGGRGTVPRVTLFRQMSSGAIPPNRGA
HCN1_PANDA	VSTLISRPHPTVGESLASIPQPVAHVGPGLQAGGRGTVPRVTLFRQMSSGAIPPNRGA
HCN1_RABBIT	VSTLISRPHPTVGESLASIPQPVAAVHSAGLQAAGRSTVPRVTLFRQMSSGAIPPNRGV
HCN1_PLATYFUS	VSTPISRPHPTVGESLASLPQPASGAQAAGFQAGSRGSVPPRVTLFQMSSGAIPPHRGV
HCN1_BIRD	ISTLIARPHPTVGESLASLPQPAPGP---GVPPGGRAGVPQRVSLFRQMSSGAIPPHRAA
HCN1_CHICKEN	ISTLIARPHPTVGESLASLPQPAPGT---SVPPASRATVPQRVSLFRQMSSGAIPPNRGA
HCN1_ANOLE	ISMMIARPHPTVGESLASIPQPLSGFQSTGLQAGNKGTVPRVALFRQMSSGAIPPTRGA
HCN1_FROG	ISTLGSKPHPTVGESLASLPQPISNVQAAGTQSGRSNIPPRVALFRQMSSGALPPARVG
HCN1_PIG	-----
HCN1_TILAPIA	TSLGPRVHPTSGDSLASICVPPTAAVIQGMNLQSGIRTTVPQRVNLFRQMSSGALPPVRSA
HCN1_PLATYFISH	TSLGPRAHPASGESELASMVPPTAACIQGISLQGGIRTTVPQRVSLFRQMSSGALPPVRSA
HCN1_TETRAODON	ASLGPRAHAPSQDSLASICVPPTAACIQMSLQGGIRTTVPQRVNLFRQMSSGALPPVRSA
HCN1_TROUT	TSLGPRAHPAASQDSLASICVPPVAAVQGMGIQSGLRTTVPQRVNLFRQMSSGALPPVRAV

HCN1_HUMAN	PPAPPPPAAALPRES-----SSVLNT--DPDAEKPRFASNL
HCN1_MACAQUE	PPAPPPPAAALPRES-----SSVLNT--DPDAEKPRFASNL
HCN1_ORANGUTAN	PPAPPPPAAALPRES-----SSVLNT--DPDAEKPRFASNL
HCN1_MARMOSET	PPAPPPPAAALPRES-----SSVLNT--DPDAEKPRFASNL
HCN1_MOUSE	PPAPPP-PAAVQRES-----PSVLNT--DPDAEKPRFASNL
HCN1_RAT	PPAPPP-PAAVQRES-----PSVLNK--DPDAEKPRFASNL
HCN1_SQUIRREL	PPAPPPPAAALQREP-----SSVLNT--DPDAEKPRFASNL
HCN1_HORSE	PPAPPPPAAALPRES-----SSVLST--DPDAEKPRFASNL
HCN1_COW	PPAPPPPAAAHPREA-----PSVLTT--DSEAEKPRFASNL
HCN1_GALAGO	PPAPPPPAAALQREA-----SSVLNT--DPEAEKPRFASNL
HCN1_DOG	PPAPPPPAAALPRES-----SSVLTT--DPEAEKPRFASNL
HCN1_PANDA	PPAPPPPAAALPRES-----SSVLTT--DPEAEKPRFASNL
HCN1_RABBIT	PPAPPPPAAALQREA-----SSVLNT--DPEAEKPRFASNL
HCN1_PLATYFUS	VPPGPPTGAPLQRDT-----SGVLNA--EPEGDKPRFASNL
HCN1_BIRD	APPAAPLQKIGRAVQ-----QECRDRYRMPEGDKPRFASNL
HCN1_CHICKEN	VPPAAMPLRDSSAVL-----STE----PEGDKPRFASNL
HCN1_ANOLE	APSAATLQRDSSTVL-----NTELEG----DKPRFASNL
HCN1_FROG	ATTQPSPAPPTKDSS-----TVSSTD----DTDKLKYSANL
HCN1_PIG	-----
HCN1_TILAPIA	AAAAAAAAAAASSSTQHRDSPGSRRDSVLSSTETEQDKMRFASNL
HCN1_PLATYFISH	ASAVAAVAAASSSTS-TQHRESPGSRRDSVLSSTETEQDKMRFASNL
HCN1_TETRAODON	AAAAAAAASSVSS-----STQQSTETEQDKLRFSSNL
HCN1_TROUT	SSAAQHRDSTGSRD-----SRRDSTSSTETEQDKMRFASNL

(b)

HCN3_HUMAN	-----
HCN4_HUMAN	-----MDKLPPSMRKRLYSLPQQVGAKAWIMDEEEDAEEEGAGGRQDPSRRSIRLRPLPSPSA
HCN2_HUMAN	-----MDARGGGGRPGESPGATPAPGPPPPPPPAPPQQQP
HCN1_HUMAN	-----

HCN3_HUMAN	-----
HCN4_HUMAN	AAGGTESRSSALGAADSEGPARGAGKSSTNGDCRRFRGSLASLGSRGGGSGGTGSGSSHG
HCN2_HUMAN	PPPPPPAPPPGPAPPQHPPRAEALPPEAADEGGPRGRRLRSRDSSCGRPAGTAASTAK
HCN1_HUMAN	-----MEGGGKPNSSNSRDDGNSVFPAKASATG

HCN3_HUMAN	-----MEAEQRPAAGASEGATPGLEAVPPVAPPATAASGPIPKSGP
HCN4_HUMAN	HLHDSAERRLLIAEGDASPAGEDRTPPGLAAEPPERPGASAQPAASPPPQQPPQPAASCE
HCN2_HUMAN	GSPNGECGRGEQCSPAGPEGPARGPVSCRGAAASGPAPGPGPAEEAGSEEAGPAGEP
HCN1_HUMAN	AGPAAAEEKRLGTGGAGAKEHGNSVCFKVDGGGGGGGGGEEPAGGFEDAEGP

HCN3_HUMAN	EP-----KRRHLGTLLQPTVNKFSLRVFGSHKAV
HCN4_HUMAN	QPSVDTAIKVVEGAAAGDQILPEAEVRLQZAGFMQRQFGAMLQPGVNKFSLRMFGSQKAV
HCN2_HUMAN	RGS-----QASFMRQFQALLQPGVNKFSLRMFGSQKAV
HCN1_HUMAN	QYG-----FMQRQFTSMLQPGVNKFSLRMFGSQKAV .
	: * : : * : * : * : * : * : * : * : * : *
HCN3_HUMAN	EIEQERVKSAGAWIIHPYSDFRFYWDLIMLLLVMGNLIVLPVGITFFKEENSPPWIVFNV
HCN4_HUMAN	EREQERVKSAGFWIIHPYSDFRFYWDLTMLLMVGNIIPVGITFFKDENTTPWIVFNV
HCN2_HUMAN	EREQERVKSAGAWIIHPYSDFRFYWDLTMLLFMVGNLIIIPVGITFFKDDETTAPWIVFNV
HCN1_HUMAN	EKEQERVKTAGFWIIHPYSDFRFYWDLIMLIMMVGNLIVPGITFFTEQTTTPWIIFNV * : * : * : * : * : * : * : * : * : * : * : * : * : * : * : * : * : *
HCN3_HUMAN	LSDTFFLLDLVLFNFRGIVVVEGAEILLAPRAIRTRYLRTWFLVLDISSLIPVDYIFLVVE
HCN4_HUMAN	VSDTFFLIDLVLFNFRGIVVVEDNTIEILDPEQRIKMKYLKSWFMVDFISSLIPVDYIFLIVE
HCN2_HUMAN	VSDTFFLMDLVLFNFRGIVIEDNTIEILDPEKIKKKYLRTWFVVDFVSSIPVDYIFLIVE
HCN1_HUMAN	ASDTVFLLDLIMNFRGTVNEDSSEIILDPKVIKMNYLKSWFVVFDFISSLIPVDYIFLIVE ***.***:***:***** * : * : * : * : * : * : * : * : * : * : * : * : * : *
HCN3_HUMAN	LEPRLDAAEVYKTARALRIVRFTKILSLLRLLRLSRLIRYIHQWEEIFHMTYDLASAVRI
HCN4_HUMAN	TR--IDSEVYKTARALRIVRFTKILSLLRLLRLSRLIRYIHQWEEIFHMTYDLASAVRI
HCN2_HUMAN	KG--IDSEVYKTARALRIVRFTKILSLLRLLRLSRLIRYIHQWEEIFHMTYDLASAVRI
HCN1_HUMAN	KG--MDSEVYKTARALRIVRFTKILSLLRLLRLSRLIRYIHQWEEIFHMTYDLASAVRI : * : * : * : * : * : * : * : * : * : * : * : * : * : * : * : * : * : *
HCN3_HUMAN	FNLIGMMLLLCHWDGCLQFLVPMQLQDFPPDCWVSINHMVNHSWGRQYSHALFKAMSHMLC
HCN4_HUMAN	VNLIGMMLLLCHWDGCLQFLVPMQLQDFPDDCWVSINNMVNNSW GKQYSYALFKAMSHMLC
HCN2_HUMAN	CNLISMMLLLCHWDGCLQFLVPMQLQDFPRNCWVSINGMVNHWS ELYSFALFKAMSHMLC
HCN1_HUMAN	FNLIGMMLLLCHWDGCLQFLVPLIQDFPPDCWVSLNEMVNDSWGKQYSYALFKAMSHMLC ***.*****:*****:***** :*****:*****.***.*****:*****
HCN3_HUMAN	IGYQQQAPVGMPDVWLTLMSIVGATCYAMFIGHATALIQLSLDSSRRQYQEKYKQVEQYM
HCN4_HUMAN	IGYGRQAPVGMSDVWLTLMSIVGATCYAMFIGHATALIQLSLDSSRRQYQEKYKQVEQYM
HCN2_HUMAN	IGYGRQAPESMTDIWLTLMSIVGATCYAMFIGHATALIQLSLDSSRRQYQEKYKQVEQYM
HCN1_HUMAN	IGYGAQAPVSMSDLWITLMSIVGATCYAMFVGHATALIQLSLDSSRRQYQEKYKQVEQYM ***** *** .*.***:*****:*****:*****:*****:*****:*****
HCN3_HUMAN	SFHKL PADTRQRIHEYEEHRYQGKMFDEESILGELSEPLREEIINFTRGLVAHmplFAH
HCN4_HUMAN	SFHKL PPDTRQRIHDYYEHR YQGKMFDEESILGELSEPLREEIINFNCRKL VASMPLFAN
HCN2_HUMAN	SFHKL PADFRQKIHDYYEHR YQGKMFDEDSILGELNGPLREEIVNFNCRKL VASMPLFAN
HCN1_HUMAN	SFHKL PADMRQKIHDYYEHR YQGKIFDEENILNE LNDPLREEIVNFNCRKL VATMPLFAN *****.** * :*****:*****:*****:*****.**.**.*****:*****.** *** ****:
HCN3_HUMAN	ADPSFVTAVLTKLRFEVFPQPGDLVVREGSVGRKMYFIQHGLLSVLARGARDTRLTDGSYF
HCN4_HUMAN	ADPNFVTSMLT KLRFEVFPQPGDYIIREGTIGKKMYFIQHGVSVLTKGNKETKLADGSYF
HCN2_HUMAN	ADPNFVTAMLT KLKFEVFPQPGDYIIREGTIGKKMYFIQHGVSVLTKGNKEMKLSDG SYF
HCN1_HUMAN	ADPNFVTAMLSKLRFEVFPQPGDYIIREGAVGKKMYFIQHG VAGVITKSSKEMKLT DGSYF ***.***:*****:***** :*****:*****:*****: .*:.. : : :*****
HCN3_HUMAN	GEICLLTRGRRRTASVRADTYCRLYSLSDHFNAVLEEFPMRRAFETVAMDRLLRIGKKN
HCN4_HUMAN	GEICLLTRGRRRTASVRADTYCRLYSLSDNFNEVLEEYPMRRAFETVALDRLLDRIGKKN
HCN2_HUMAN	GEICLLTRGRRRTASVRADTYCRLYSLSDNFNEVLEEYPMRRAFETVAIDLDRIGKKN
HCN1_HUMAN	GEICLLTKGRRTASVRADTYCRLYSLSDNFNEVLEEYPMRRAFETVAIDLDRIGKKN *****:*****:*****:*****:*****:*****:*****:*****
HCN3_HUMAN	SILQRKRSEPSPG---SSGGIMEQHLVQH DMRGVRGRAPSTGAQLSGKPVLWEPLV
HCN4_HUMAN	SILLHKVQHDLNSGVFNQYQENEIIQQIVQH DREMAHCAHRVQAAASATPTPTPVIVTPLI
HCN2_HUMAN	SILLHKVQHDLNSGVFNQENAI IQEIVKYDREMVQQAELGQRVGLFFFFFFFQVTSAI
HCN1_HUMAN	SILLQKFQKDLNTGVFNQENEILKQIVKH DREMVQAIAPINYPQM TTLNSTSSTT PTS *** :* : . : * : * : * : . .
HCN3_HUMAN	HAPLQAAAVTSVIAI ALTHQ-----
HCN4_HUMAN	QAPLQAAAATSVIAI ALTHHPRLPAI FRPPPGS GLGNLGAGQT PRHLKRL QSLIPS ALG
HCN2_HUMAN	ATLQQAAAAMSFCPQVARPLVG-----
HCN1_HUMAN	RMRTQSPPVYTATSLSHSNLHSPSPSTQTPQPSAILSPCSYTTAVCSPPVQ SPLAARTFH *:.. : : .
HCN3_HUMAN	-----
HCN4_HUMAN	SASPASSPSQVDTPSSSFHIQQLAGFSAPAGLSPLLPSSSSPPPGACGSPSAPTPSAG
HCN2_HUMAN	-----
HCN1_HUMAN	YASPTASQLSLMQQP-----
HCN3_HUMAN	-----
HCN4_HUMAN	VAATTIAGFGHFHKALGGSLSSDSPLTLPQPGARSPQAAQPSAPP GARGGLGLP EHF
HCN2_HUMAN	-----

HCN1_HUMAN

-----RGLPLSPDSPATLLARSAWRSAAGSPASPLV
LPPPPSSRSPSSSPGQLGQPPGELSLGLATGPLSTPETPRQPEPPSLVAGASGGASPVG
-----PLALGSPLRVRRPPPAPAPAASPGPPPP
-----QQVQQSQPPQTQPQQSPQPQTPGSSTPKN
 *

HCN3_HUMAN PVRAGPWASTSRLPAPPARTLHASLSRAGRSQVSLLGPPP-----
HCN4_HUMAN FTPRGGLSPPGHSPGPRTFPSAPPRASGSHGSSLPPASSPPPQVPQRRTPPLTPGR
HCN2_HUMAN ASPPGAPASPRAPRTSPYGGLPAAAPLAGPALPARRLSRAS-----
HCN1_HUMAN EVHKSTQALHTNTNLTREVRPLSASQPSLPHEVSTLISRPHPTVG-----
 *.

HCN3_HUMAN -----GGGGRRRLGPR
HCN4_HUMAN LTQDLKLISASQPALPQDGQAQTLRRASPHSGESMAAFPLFPRAGGGSGSGSSGGLGPP
HCN2_HUMAN -----RPLSASQP
HCN1_HUMAN -----ESLASIPQPVTAVPGTGL

HCN3_HUMAN GRPLSASQPSLPQRATGDGSPGRKGSGSERLPPSGLLAKKPRTAQPPRPPVPEPATPRGL
HCN4_HUMAN GRPYGAIPGQHVTLPRTKTSQGSLPPPLSLFGARATSSGGPLTAGPQREPGRPEPVRSK
HCN2_HUMAN SLPHGAPGPASTRPASSSTPRLGPTPAARAAAPSPDRRDASPAGAAGGLDPQDSARSRL
HCN1_HUMAN QAGGRSTVQRVTLFRQMSSGAIPPNRGVPPAPPAAAALPRESSSVLNTDPDAEKPRFA
 .:

HCN3_HUMAN QLSANM
HCN4_HUMAN LPSNL-
HCN2_HUMAN SSNL--
HCN1_HUMAN SNL---

Multiple pairwise alignments of HCN1 orthologous (a) and paralogous (b) sequences were performed using Clustalw 2.1 (<http://www.genome.jp/tools/clustalw/>). The amino acids altered by the mutations are highlighted.